[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 149
1. Meer S, Altini M: Sclerosing polycystic adenosis of the buccal mucosa. Head Neck Pathol; 2008 Mar;2(1):31-5
MedlinePlus Health Information. consumer health - Mouth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing polycystic adenosis of the buccal mucosa.
  • Sclerosing polycystic adenosis (SPA) is a rare lesion of salivary glands with a striking resemblance to fibrocystic disease of the breast.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2002 Jan;440(1):29-35 [11942573.001]
  • [Cites] Acta Cytol. 2004 Jul-Aug;48(4):569-73 [15296349.001]
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):161-70 [8554105.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):154-64 [16434888.001]
  • [Cites] Histopathology. 2007 Jul;51(1):1-20 [17539914.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Oct;104(4):516-20 [17150380.001]
  • [Cites] Br J Oral Maxillofac Surg. 2007 Jan;45(1):74-6 [16054736.001]
  • [Cites] B-ENT. 2006;2(4):189-92 [17256407.001]
  • [Cites] Diagn Cytopathol. 2007 Jul;35(7):444-7 [17580340.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):939-44 [16861963.001]
  • (PMID = 20614339.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2807607
  • [Keywords] NOTNLM ; Immunohistochemistry / Salivary glands / Sclerosing polycystic adenosis
  •  go-up   go-down


2. Celis JE, Moreira JM, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans V, Rank F: Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol Oncol; 2007 Jun;1(1):97-119
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
  • The identification as well as the molecular characterization of breast precancerous lesions in terms of increased risk of progression and/or recurrence is becoming a critical issue today as improved non-surgical procedures are detecting cancer at an earlier stage.
  • The strategy we have been pursuing to identify early apocrine breast lesions is based on the postulate that invasive apocrine carcinomas evolve from epithelial cells in terminal duct lobular units (TDLUs) in a stepwise manner that involves apocrine metaplasia of normal breast epithelia, hyperplasia, atypia, and apocrine carcinoma in situ.
  • Here we present studies in which we have used antibodies against components of a benign apocrine signature that includes 15-prostaglandin dehydrogenase (15-PGDH), a protein that is expressed by all benign apocrine lesions, and markers that are highly overexpressed by pure invasive apocrine carcinomas such as MRP14 (S100A9), psoriasin (S100A7), and p53 to identify precancerous lesions in sclerosing adenosis (SA) with apocrine metaplasia.
  • The latter is a benign proliferative lesion of the breast that exhibits an increase in the size of the TDLUs and characterized by retained two-cell lining, and myoepithelial (ME) and stromal hyperplasia.
  • SA with apocrine metaplasia, i.e. apocrine adenosis (AA), presents with a higher degree of atypical apocrine hyperplasia, and these lesions are believed to be precursors of apocrine carcinoma, in situ and invasive.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Fibrocystic Breast Disease / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):39-50 [11801722.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):785-93; discussion 793 [12454517.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):75-85 [17009105.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1873-84 [9412479.001]
  • [Cites] Adv Anat Pathol. 2004 Jan;11(1):1-9 [14676636.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):6-14 [15797289.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):146-9 [7819031.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S80-3 [10517446.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] Am J Surg. 1990 May;159(5):473-8 [2334010.001]
  • [Cites] J Pathol. 2004 Mar;202(3):274-85 [14991892.001]
  • [Cites] Virchows Arch. 1998 Mar;432(3):255-60 [9532005.001]
  • [Cites] Am J Surg. 1993 Sep;166(3):237-43 [8368433.001]
  • [Cites] J Cutan Pathol. 1999 Mar;26(3):113-8 [10235375.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1316-23 [16835330.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):555-69 [15644556.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):26-41 [19383285.001]
  • [Cites] Anticancer Res. 1988 Nov-Dec;8(6):1217-22 [3064712.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):693-7 [10505026.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):13-8 [10658905.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1622-31 [16846592.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):737-46 [12065684.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):323-9 [10880402.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):355-61 [10197443.001]
  • [Cites] Ir J Med Sci. 1989 Jun;158(6):137-40 [2570047.001]
  • [Cites] Recent Results Cancer Res. 1998;152:11-21 [9928543.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Trends Cell Biol. 1996 Sep;6(9):341-7 [15157431.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):87-101 [17420292.001]
  • [Cites] Breast Cancer Res. 2003;5(5):R151-6 [12927046.001]
  • [Cites] BMJ. 1997 Mar 29;314(7085):925-8 [9099114.001]
  • [Cites] J Dermatol Sci. 2007 Feb;45(2):147-50 [17071058.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Virchows Arch. 2006 May;448(5):525-31 [16570182.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2805-9 [7872722.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):261-72 [16807805.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1340-2 [11684218.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):470-9 [9469330.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7818-23 [16885386.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Med Princ Pract. 2007;16(1):1-14 [17159357.001]
  • [Cites] Subcell Biochem. 1998;31:205-62 [9932494.001]
  • [Cites] J Invest Dermatol. 1991 Oct;97(4):701-12 [1940442.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4782-90 [8840999.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1033-67 [17158753.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2529-37 [8640702.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1473-81 [16273201.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] FEBS J. 2005 Jan;272(1):2-15 [15634327.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:49-52 [2141459.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2006 Oct;81(1-2):14-30 [16997128.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):462-83 [16316978.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):185-97 [11981114.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):344-9 [16400324.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):349-54 [10197442.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):737-42 [7560201.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):369-72 [7927943.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] Eur J Gynaecol Oncol. 1992;13(4):309-15 [1325346.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):207-14 [11141494.001]
  • [Cites] JAMA. 1995 Jan 11;273(2):149-54 [7799496.001]
  • [Cites] Breast Cancer Res. 2005;7(5):190-7 [16168137.001]
  • [Cites] Mol Cell Proteomics. 2003 Jun;2(6):369-77 [12832461.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1307-12 [17182657.001]
  • [Cites] Methods. 2003 Jul;30(3):247-55 [12798139.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5 Suppl 1):S3-18 [11993707.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):675-81 [15220356.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]
  • [Cites] Dev Biol. 1999 Feb 1;206(1):88-99 [9918697.001]
  • [Cites] Histopathology. 2001 Mar;38(3):221-4 [11260302.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(2):93-109 [11519870.001]
  • [Cites] Breast. 2002 Dec;11(6):466-72 [14965711.001]
  • [Cites] J Pathol. 2002 Mar;196(3):287-91 [11857491.001]
  • [Cites] J Mol Biol. 1993 Jun 20;231(4):982-98 [8515476.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6):642-6 [17145342.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):835-41 [10842198.001]
  • [Cites] Med Mol Morphol. 2006 Mar;39(1):8-13 [16575508.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):638-42 [17136094.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1051-61 [15254552.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):749-51 [10797302.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):381-6 [3557440.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):449-55 [12447674.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1076-91 [15252316.001]
  • [Cites] Differentiation. 1998 Aug;63(4):201-13 [9745711.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):1-5 [2020652.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):387-94 [17079091.001]
  • [Cites] Histopathology. 2001 Oct;39(4):433-4 [11683946.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2328-38 [16314837.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11326-34 [16357139.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1179-87 [15110881.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):61-74 [15886887.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):492-522 [15695426.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):43-7 [11782356.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):687-94 [2058763.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):327-44 [14754989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):3003-9 [10383167.001]
  • [Cites] Pathology. 2006 Feb;38(1):16-20 [16484002.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):337-42 [8163266.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] J Endocrinol. 1992 Mar;132(3):R5-8 [1564416.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • [Cites] Cancer Detect Prev. 2001;25(3):262-7 [11425268.001]
  • (PMID = 19383289.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


3. Cebesoy FB, Kutlar I, Aydin A: Vaginal adenosis successfully treated with simple unipolar cauterization. J Natl Med Assoc; 2007 Feb;99(2):166-7
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginal adenosis successfully treated with simple unipolar cauterization.
  • Vaginal adenosis, without a history of diethylstilbestrol (DES) exposure, is a rare condition with an unclear etiology.
  • Histopathologic examination of the lesions revealed vaginal adenosis with chronic inflammation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Gynaecol Oncol. 2001;22(4):260-2 [11695804.001]
  • [Cites] Obstet Gynecol. 1984 Apr;63(4):601-2 [6700910.001]
  • [Cites] Gynecol Obstet Invest. 2001;51(4):271-3 [11408740.001]
  • [Cites] Am J Obstet Gynecol. 1965 Sep 15;93:209-22 [14336650.001]
  • [Cites] Br J Dermatol. 1998 Jul;139(1):128-31 [9764164.001]
  • (PMID = 17366953.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2569442
  •  go-up   go-down


Advertisement
4. Perottino F, Barnoud R, Ambrun A, Poupart M, Pignat JC, Merrot O: Sclerosing polycystic adenosis of the parotid gland: diagnosis and management. Eur Ann Otorhinolaryngol Head Neck Dis; 2010 Mar;127(1):20-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing polycystic adenosis of the parotid gland: diagnosis and management.
  • OBJECTIVE: To describe diagnostic and therapeutic management of a rare parotid lesion: sclerosing polycystic adenosis.
  • Conservative subtotal parotidectomy diagnosed sclerosing polycystic adenosis.
  • CONCLUSION: Sclerosing polycystic adenosis of the parotid gland is a rare and recently described entity presenting several analogies to the much more frequent cystic mastitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 20822751.001).
  • [ISSN] 1879-730X
  • [Journal-full-title] European annals of otorhinolaryngology, head and neck diseases
  • [ISO-abbreviation] Eur Ann Otorhinolaryngol Head Neck Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Paczos TA, Ackers S, Odunsi K, Lele S, Mhawech-Fauceglia P: Primary vaginal adenocarcinoma arising in vaginal adenosis after CO2 laser vaporization and 5-fluorouracil therapy. Int J Gynecol Pathol; 2010 Mar;29(2):193-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary vaginal adenocarcinoma arising in vaginal adenosis after CO2 laser vaporization and 5-fluorouracil therapy.
  • The vaginectomy specimen showed residual adenocarcinoma associated with VAIN-III and extensive vaginal adenosis with free resection margins.
  • This is the second reported case in the literature of adenocarcinoma arising in vaginal adenosis after 5-fluorouracil.
  • Herein, we highlight these important findings and shed some light on the pathogenesis of vaginal adenosis and the subsequent development of vaginal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173507.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA108456
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Elayat G, Selim AG, Wells CA: Cell cycle alterations and their relationship to proliferation in apocrine adenosis of the breast. Histopathology; 2009 Feb;54(3):348-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle alterations and their relationship to proliferation in apocrine adenosis of the breast.
  • AIMS: Apocrine adenosis (AA) is generally considered a benign disease of the breast.
  • The aim was to investigate the status of cell cycle proteins previously reported to be deregulated in breast cancer to identify their possible role in AA.
  • Furthermore, proliferation in AA (4.5%) was significantly higher than that of normal breast epithelium (1%).
  • [MeSH-major] Breast / pathology. Cell Cycle / physiology. Cell Proliferation. Fibrocystic Breast Disease / pathology
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / metabolism. Cell Cycle Proteins / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236511.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins
  •  go-up   go-down


7. Elayat G, Selim AG, Wells CA: Cell turnover in apocrine metaplasia and apocrine adenosis of the breast. Ann Diagn Pathol; 2010 Feb;14(1):1-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
  • Apocrine metaplasia (APM) is a common finding in the breast of postmenopausal women and is seen in a broad spectrum of lesions ranging from microscopic cysts to invasive apocrine carcinoma.
  • Apocrine metaplasia within sclerosing adenosis is known as apocrine adenosis (AA) and is considered a benign lesion of the breast.
  • The results showed that all cases studied by immunohistochemistry were positive for the expression of Bak, Mcl-1, Bcl-x, and Bcl-x(L) showing a pattern of staining similar to that seen in the normal breast epithelium.
  • There was no statistical significance between the AI of these 2 groups and that of the normal breast epithelium (0.3%).
  • There was no statistical significance between the AI of these 2 groups and that of the normal breast epithelium (0.3%).
  • [MeSH-major] Apocrine Glands / pathology. Breast / pathology. Breast Neoplasms / pathology. Fibrocystic Breast Disease / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20123450.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAK1 protein, human; 0 / BCL2L1 protein, human; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-X Protein; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


8. Watanabe K, Nomura M, Hashimoto Y, Hanzawa M, Hoshi T: Fine-needle aspiration cytology of apocrine adenosis of the breast: report on three cases. Diagn Cytopathol; 2007 May;35(5):296-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytology of apocrine adenosis of the breast: report on three cases.
  • Apocrine adenosis is a distinctive breast lesion, which can sometimes be misdiagnosed as malignant histologically.
  • We report fine-needle aspiration (FNA) cytology of three cases of apocrine adenosis.
  • Although FNA cytology of apocrine adenosis has the potential to be misinterpreted as malignant, the naked nuclei of background and less hyperchromatic nuclear features may be useful in distinguishing apocrine adenosis from carcinoma.
  • Being familiar with these distinctive breast lesions is also important in decreasing false positives.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Fibrocystic Breast Disease / pathology
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427223.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Lee YH, Dai YC, Lin IL, Tu CW: Young-aged woman with invasive ductal carcinoma arising in atypical microglandular adenosis: a case report. Pathol Int; 2010 Oct;60(10):685-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Young-aged woman with invasive ductal carcinoma arising in atypical microglandular adenosis: a case report.
  • Microglandular adenosis (MGA) and atypical microglandular adenosis (AMGA) are extremely rare and unique forms of adenosis of the breast.
  • Both forms of adenosis are strongly associated with carcinoma arising in microglandular adenosis (MGACA) and are recognised as precursor lesions of invasive breast carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Fibrocystic Breast Disease / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Pathology International © 2010 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.
  • [ErratumIn] Pathol Int. 2010 Dec;60(12):798
  • (PMID = 20846267.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


10. Shui R, Yang W: Invasive breast carcinoma arising in microglandular adenosis: a case report and review of the literature. Breast J; 2009 Nov-Dec;15(6):653-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive breast carcinoma arising in microglandular adenosis: a case report and review of the literature.
  • Microglandular adenosis of the breast is an extremely rare, benign lesion.
  • Carcinoma arising in microglandular adenosis has been reported in up to 27% of patients with microglandular adenosis.
  • We reported a case of invasive carcinoma arising in microglandular adenosis.
  • A lumpectomy was performed on a 42-year-old female because of a mass in the right breast.
  • Histologically, this case was consistent with carcinoma arising in microglandular adenosis and showed clear transition from microglandular adenosis through atypical microglandular adenosis to in situ and invasive carcinoma.
  • Periodic acid-Schiff staining showed the presence of a basement membrane in microglandular adenosis, atypical microglandular adenosis, in situ carcinoma and the absence in invasive carcinoma.
  • To the best of our knowledge, this is the first reported case of carcinoma arising in microglandular adenosis in China.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Fibrocystic Breast Disease / pathology


11. Ambrosini-Spaltro A, Morandi L, Spagnolo DV, Cavazza A, Brisigotti M, Damiani S, Jain S, Eusebi V: Nasal seromucinous hamartoma (microglandular adenosis of the nose): a morphological and molecular study of five cases. Virchows Arch; 2010 Dec;457(6):727-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal seromucinous hamartoma (microglandular adenosis of the nose): a morphological and molecular study of five cases.
  • It is concluded that nasal seromucinous hamartomas are benign glandular proliferations that may resemble microglandular adenosis of the breast.
  • [MeSH-major] Hamartoma / metabolism. Hamartoma / pathology. Nose Diseases / metabolism. Nose Diseases / pathology

  • MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 1992 Jul-Aug;14 (4):321-7 [1517084.001]
  • [Cites] Laryngoscope. 1983 Apr;93(4):494-7 [6834978.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Aug;104(8):639-45 [7639474.001]
  • [Cites] Am J Surg Pathol. 2009 Mar;33(3):401-8 [19011560.001]
  • [Cites] Hum Mutat. 2003 Apr;21(4):441-3 [12655558.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):14-23 [16612623.001]
  • [Cites] Mitochondrion. 2009 Sep;9(5):318-25 [19426839.001]
  • [Cites] Mutat Res. 2009 Mar 9;662(1-2):28-32 [19114048.001]
  • [Cites] Am J Rhinol. 2006 Nov-Dec;20(6):586-90 [17181098.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1974 Nov;38(5):760-2 [4530965.001]
  • [Cites] Head Neck Pathol. 2010 Mar;4(1):77-83 [20237993.001]
  • [Cites] J Gastroenterol. 2004 Nov;39(11):1063-8 [15580399.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]
  • [Cites] Adv Anat Pathol. 2007 Jan;14(1):11-6 [17198306.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):147-50 [11381261.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Apr;264(4):451-3 [17089137.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1576-80 [17122514.001]
  • [Cites] Am J Surg Pathol. 1993 Feb;17(2):99-109 [8422116.001]
  • [Cites] Am J Surg Pathol. 1983 Dec;7(8):731-7 [6660348.001]
  • [Cites] Histopathology. 1983 Mar;7(2):169-80 [6852780.001]
  • [Cites] Lung Cancer. 2007 Apr;56(1):35-42 [17241687.001]
  • [Cites] Histopathology. 2000 Apr;36(4):376-7 [10841649.001]
  • [Cites] Am J Surg Pathol. 1983 Mar;7(2):137-44 [6859388.001]
  • [Cites] Laryngorhinootologie. 2003 Jun;82(6):416-20 [12851849.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5636-41 [14654546.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3517-25 [15908662.001]
  • [Cites] Histopathology. 2009 Jan;54(2):205-13 [19207945.001]
  • (PMID = 20922408.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Collagen Type IV; 0 / Laminin; 0 / Mucin-1; 0 / S100 Proteins
  •  go-up   go-down


12. Pérez-Campos A, Pérez F, Tejerina E, Sánchez-Yuste R, Jiménez-Heffernan JA: Fine needle aspiration cytology of atypical apocrine adenosis of the breast. Cytopathology; 2009 Apr;20(2):139-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of atypical apocrine adenosis of the breast.
  • [MeSH-major] Biopsy, Fine-Needle. Breast / pathology. Fibrocystic Breast Disease

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916092.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


13. Salarieh A, Sneige N: Breast carcinoma arising in microglandular adenosis: a review of the literature. Arch Pathol Lab Med; 2007 Sep;131(9):1397-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for microglandular adenosis .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma arising in microglandular adenosis: a review of the literature.
  • Microglandular adenosis is widely known as a benign breast lesion that can produce a mass.
  • It differs from other types of adenosis by having an infiltrative pattern of growth and glands lacking a myoepithelial layer.
  • Most cases of microglandular adenosis are resolved after adequate excision, but more recent data suggest that this lesion may be a precursor for carcinoma, with atypical microglandular adenosis being an intermediate lesion.
  • Carcinomas arising in a background of microglandular adenosis, although they may be low grade, are commonly estrogen and progesterone receptor negative, in contrast to most conventional low-grade carcinomas unrelated to microglandular adenosis.
  • They also show immunopositivity for S100 protein, similar to microglandular adenosis.
  • Diagnostic problems include differentiating microglandular adenosis from carcinoma and assessing the extent of the carcinoma component.
  • In this review, we discuss the histomorphologic and immunophenotypic characteristic of the spectrum of microglandular adenosis lesions with emphasis on diagnostic features distinguishing microglandular adenosis from well-differentiated carcinoma, in particular, tubular carcinoma, and assessment of surgical margins of excision in such lesions.
  • [MeSH-major] Breast Neoplasms / diagnosis. Fibrocystic Breast Disease / diagnosis
  • [MeSH-minor] Breast / metabolism. Breast / pathology. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. S100 Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824796.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins
  • [Number-of-references] 10
  •  go-up   go-down


14. Shin SJ, Simpson PT, Da Silva L, Jayanthan J, Reid L, Lakhani SR, Rosen PP: Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma. Am J Surg Pathol; 2009 Apr;33(4):496-504
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
  • Microglandular adenosis (MGA) is an uncommon, benign breast lesion that is characterized by a proliferation of small uniform, round glands lined by a single layer of epithelial cells around open lumina with haphazard infiltrative growth in fibrous and fatty breast tissue.
  • Such widespread genetic changes, together with recurrent loss of 5q and gain of 8q were reminiscent of those reported specifically for basal-like, estrogen receptor-negative, and BRCA1-associated breast tumors.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Chromosome Aberrations. Fibrocystic Breast Disease / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047897.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


15. Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N: Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Am J Surg Pathol; 2008 Apr;32(4):544-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
  • Microglandular adenosis (MGA) of the breast is widely known as a benign lesion that can mimic invasive carcinoma.
  • Eleven out of 65 cases qualified to have an MGA component; myoepithelial layer was detected in the remaining 54 cases and were classified as adenosis.
  • Although all the MGACA cases were triple negative and express EGFR (basal-like features), all the cases in our study showed a luminal type of differentiation by CK8/18 expression, indicating that MGACA may not fit well into the current proposed molecular classification of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma / pathology. Cell Transformation, Neoplastic / pathology. Fibrocystic Breast Disease / pathology. Immunohistochemistry. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300793.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / S100 Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


16. Unal B, Gur AS, Bhargava R, Edington H, Ahrendt G, Soran A: Intraductal location of the sclerosing adenosis of the breast. Bratisl Lek Listy; 2009;110(4):251-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal location of the sclerosing adenosis of the breast.
  • Sclerosing adenosis is a benign breast disease with non-specific images on ultrasound or mammogram.
  • Herein we present a patient with breast cancer who received neoadjuvant chemotherapy and subsequently underwent mastectomy.
  • Ductoscopy was performed to the mastectomised breast specimen as per the ductoscopy research protocol.
  • The lesions were reported as sclerosing adenosis by pathologist.
  • As to our knowledge, this is the first case in literature that demonstrates the use of ductoscopy in diagnosing the sclerosing adenosis in the breast tissue.
  • Ductoscopy and development of ductoscopy guided biopsy techniques may be used as an early diagnostic method for the ductal breast lesions (Fig.
  • [MeSH-major] Fibrocystic Breast Disease / pathology
  • [MeSH-minor] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Diagnosis, Differential. Female. Humans. Sclerosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19507655.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


17. Geyer FC, Kushner YB, Lambros MB, Natrajan R, Mackay A, Tamber N, Fenwick K, Purnell D, Ashworth A, Walker RA, Reis-Filho JS: Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma. Histopathology; 2009 Dec;55(6):732-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma.
  • AIMS: Microglandular adenosis (MGA) is a rare breast lesion, which has long been considered to be hyperplastic.
  • CONCLUSIONS: Similar to adenomas, MGA is, at least in some cases, a clonal lesion and may be a non-obligate precursor of a subgroup of high-grade triple-negative and basal-like breast carcinomas.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / genetics. Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Fibrocystic Breast Disease / diagnosis. Fibrocystic Breast Disease / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922592.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Bharadwaj G, Nawroz I, O'Regan B: Sclerosing polycystic adenosis of the parotid gland. Br J Oral Maxillofac Surg; 2007 Jan;45(1):74-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing polycystic adenosis of the parotid gland.
  • Sclerosing polycystic adenosis of the major salivary glands is rare and can simulate a slow growing tumour.
  • It is pseudoencapsulated and includes tubuloacinar adenosis with dilated ducts, apocrine metaplasia, epithelial hyperplasia, and cystic changes associated with fibrosis.
  • The histological appearance of the lesion is similar to that of fibrocystic disease of the breast.
  • We report a case of sclerosing polycystic adenosis in a 45-year-old white woman.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054736.001).
  • [ISSN] 0266-4356
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


19. Balan R, Amălinei C, Pricop F, Gheorghiţă V, Pintilie I, Ivan L, Cotuţiu C: [Diagnostic difficulties in mammary gland adenosis. Case report]. Rev Med Chir Soc Med Nat Iasi; 2005 Apr-Jun;109(2):351-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic difficulties in mammary gland adenosis. Case report].
  • Tumor adenosis represents a rare lesion, which most frequent appears as a palpable mass, with more than the usual dimensions.
  • The paper presents a case of tumor adenosis of the mammary gland of a 16 years girl.
  • Microscopically, there were observed several histologic types of adenosis, the most frequent being sclerosing adenosis.
  • The presence of these elements led through the diagnosis of tumor adenosis.
  • The importance of recognition of the tumor adenosis is found in the possibility of wrong interpretation of this with tubular invasive carcinoma, these two entities being often mistaken, mainly at the frozen-section examination.
  • [MeSH-major] Fibrocystic Breast Disease / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Breast Neoplasms / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Silver Staining

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607799.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


20. Da Silva L, Buck L, Simpson PT, Reid L, McCallum N, Madigan BJ, Lakhani SR: Molecular and morphological analysis of adenoid cystic carcinoma of the breast with synchronous tubular adenosis. Virchows Arch; 2009 Jan;454(1):107-14
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and morphological analysis of adenoid cystic carcinoma of the breast with synchronous tubular adenosis.
  • Adenoid cystic carcinoma (ACC) of the breast is a rare tumour.
  • Its recognition as a special type of breast carcinoma is very important because its prognosis is better than the not-otherwise-specified invasive ductal carcinoma and its treatment may not include axillary dissection.
  • Tubular adenosis (TA) is a very rare condition of the breast that is histologically benign; however, it has been described in association with invasive ductal carcinoma.
  • There are scant data regarding the molecular genomic alterations in ACC of the breast and no data has been presented on TA.
  • Herein, we provide a morphological characterisation of TA arising synchronically with ACC in the breast.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / complications. Carcinoma, Adenoid Cystic / pathology. Fibrocystic Breast Disease / complications. Fibrocystic Breast Disease / pathology
  • [MeSH-minor] Actins / metabolism. Breast / metabolism. Breast / pathology. Cell Proliferation. DNA, Neoplasm. Female. Genomic Instability / genetics. Humans. Keratin-19 / metabolism. Keratin-7 / metabolism. Middle Aged. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Apr 15;94(8):2119-27 [12001107.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):413-20 [11914618.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Aug;82(2):187-92 [8863309.001]
  • [Cites] Lab Invest. 2007 May;87(5):430-9 [17372589.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1276-81 [2824330.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):46-54 [8540608.001]
  • [Cites] Am J Surg Pathol. 1986 Apr;10(4):237-45 [3706610.001]
  • [Cites] Cancer. 1975 Jul;36(1):1-85 [173455.001]
  • [Cites] Cytometry. 1998 Mar 1;31(3):163-73 [9515715.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4185-91 [16857790.001]
  • [Cites] J Microsc. 2005 Apr;218(Pt 1):52-61 [15817063.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1623-31 [16258515.001]
  • [Cites] Breast Cancer Res Treat. 2005 Oct;93(3):189-90 [16142443.001]
  • [Cites] Ann Diagn Pathol. 2004 Feb;8(1):39-42 [15129910.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):119-22 [9504855.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jun;101(6):302-6 [193456.001]
  • [Cites] Lab Invest. 2008 May;88(5):464-73 [18332873.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R4 [17217540.001]
  • [Cites] Semin Diagn Pathol. 2003 Nov;20(4):279-304 [14694981.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):250-8 [8625100.001]
  • [Cites] Histopathology. 1987 Mar;11(3):305-15 [2828217.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] J Pathol. 2008 Oct;216(2):141-50 [18720457.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):544-52 [18300793.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1052-60 [12883237.001]
  • [Cites] Breast Cancer Res. 2007;9(5):R65 [17910759.001]
  • [Cites] Am J Clin Pathol. 1993 Nov;100(5):507-13 [7504394.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):831-6 [10879734.001]
  • [Cites] Surg Gynecol Obstet. 1966 Jun;122(6):1289-94 [5941852.001]
  • [Cites] Int Semin Surg Oncol. 2006 Jun 30;3:17 [16813652.001]
  • [Cites] Int J Surg Pathol. 2000 Oct;8(4):303-315 [11494007.001]
  • [Cites] Am J Surg Pathol. 1993 Feb;17(2):99-109 [8422116.001]
  • [Cites] Breast Cancer Res Treat. 2004 Oct;87(3):225-32 [15528965.001]
  • [Cites] Am J Surg Pathol. 1983 Dec;7(8):731-7 [6660348.001]
  • [Cites] Histopathology. 1983 Mar;7(2):169-80 [6852780.001]
  • [Cites] Cancer. 1969 Oct;24(4):740-5 [4309694.001]
  • [Cites] J Clin Pathol. 1975 Aug;28(8):647-55 [171285.001]
  • [Cites] Am J Surg Pathol. 1983 Mar;7(2):137-44 [6859388.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):782-9 [10741697.001]
  • [Cites] Am J Clin Pathol. 1973 May;59(5):653-8 [4349849.001]
  • [Cites] J Pathol. 2005 Nov;207(3):260-8 [16167361.001]
  • [Cites] Eur J Cancer. 1995 Dec;31A(13-14):2289-95 [8652258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • (PMID = 19031084.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / DNA, Neoplasm; 0 / Keratin-19; 0 / Keratin-7; 0 / S100 Proteins
  •  go-up   go-down


21. González Gleason A, Vera Gaspar D, López Castañares C: [Vaginal adenosis and vaginal intraepithelial neoplasia: a review of the literature and a case report]. Ginecol Obstet Mex; 2009 Jul;77(7):329-34
MedlinePlus Health Information. consumer health - Vaginal Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vaginal adenosis and vaginal intraepithelial neoplasia: a review of the literature and a case report].
  • [Transliterated title] Adenosis vaginal y neoplasia intraepitelial de vagina: revisión de la bibliografia y reporte de un caso.
  • Vaginal adenosis is an uncommon pathology, characterized by the presence of cylindrical epithelium in the vagina.
  • This paper aims at reviewing the literature on vaginal adenosis, vaginal intraepithelial neoplasia and their possible treatments.
  • In addition, the paper reports on a case of vaginal adenosis in a young female patient with concomitant VAIN 2, the CO2 laser ablation performed, and the short-term results obtained.

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19681363.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 13
  •  go-up   go-down


22. Facina G, Lopes-Costa PV, Dos Santos AR, De Vasconcelos-Valença RJ, Pinho-Sobral AL, Ferreira-Filho CP, Alencar AP, Gebrim LH, Da Silva BB: Immunohistochemical expression of E-cadherin in sclerosing adenosis, ductal carcinoma in situ and invasive ductal carcinoma of the breast. Diagn Cytopathol; 2010 Apr;38(4):235-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of E-cadherin in sclerosing adenosis, ductal carcinoma in situ and invasive ductal carcinoma of the breast.
  • E-cadherin (EC) is an important glycoprotein cell-adhesion molecule that appears to play a significant role in the progression of breast lesions.
  • The objective of this study was to evaluate EC expression in sclerosing adenosis, ductal carcinoma in situ and invasive ductal carcinoma.
  • Samples of breast lesions from 44 women were used in this study, comprising cases of sclerosing adenosis (n = 11), ductal carcinoma in situ (DCIS) (n = 10) and invasive ductal carcinoma (n = 23).
  • This difference was statistically significant when sclerosing adenosis was compared with DCIS (P < 0.0002), when sclerosing adenosis was compared with invasive ductal carcinoma (P < 0.008) and when DCIS was compared with invasive ductal carcinoma (P < 0.007).
  • The present findings point to a significant association between reduced EC expression and the progression and aggressivity of breast lesions. Diagn. Cytopathol.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cadherins / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19790246.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins
  •  go-up   go-down


23. Kazakov DV, Bisceglia M, Sima R, Michal M: Adenosis tumor of anogenital mammary-like glands: a case report and demonstration of clonality by HUMARA assay. J Cutan Pathol; 2006 Jan;33(1):43-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosis tumor of anogenital mammary-like glands: a case report and demonstration of clonality by HUMARA assay.
  • In mammary pathology, adenosis tumor is defined as a clinically recognizable lesion that histologically primarily consists of adenosis, but also exhibits various combinations of diverse epithelial changes seen in other benign breast diseases.
  • A lesion that occurred in the anogenital area of a 46-year-old woman and apparently arose in anogenital mammary-like glands is described and which, in our opinion, is best classified as adenosis tumor.
  • Several histological patterns within the same tumor mass were recognizable: sclerosing adenosis-like changes, variably sized microcysts and cysts, some with rare short papillary projections having hyalinized cores, rare tubular structures exhibiting epithelial features reminiscent of simple ductal hyperplasia, areas with oxyphilic (apocrine) metaplasia, and clear cell epithelial changes resembling mucinous metaplasia.
  • As our case exhibited a number of patterns identical to those seen in diverse benign breast diseases, its classification as adenosis tumor seems justifiable.
  • [MeSH-major] Anus Neoplasms / pathology. Fibrocystic Breast Disease / pathology. Mammary Glands, Human / pathology. Receptors, Androgen / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16441411.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers, Tumor; 0 / Receptors, Androgen
  •  go-up   go-down


24. El Aouni N, Balleyguier C, Mansouri D, Mathieu MC, Suciu V, Delaloge S, Vielh P: Adenosis tumor of the breast: cytological and radiological features of a case confirmed by histology. Diagn Cytopathol; 2008 Jul;36(7):496-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosis tumor of the breast: cytological and radiological features of a case confirmed by histology.
  • We report the case of a 63-year-old woman who presented with a right breast lump detected by screening mammography.
  • A core needle biopsy performed to rule out a breast cancer revealed an adenosis tumor of the breast.
  • [MeSH-major] Biopsy, Fine-Needle. Fibrocystic Breast Disease / diagnosis
  • [MeSH-minor] Breast / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography. Female. Humans. Mammography. Middle Aged. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18528894.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Etit D, Pilch BZ, Osgood R, Faquin WC: Fine-needle aspiration biopsy findings in sclerosing polycystic adenosis of the parotid gland. Diagn Cytopathol; 2007 Jul;35(7):444-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy findings in sclerosing polycystic adenosis of the parotid gland.
  • Sclerosing polycystic adenosis (SPA) is a recently described, rare lesion of the salivary gland analogous to fibrocystic disease of the breast.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580340.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Visscher DW: Apocrine ductal carcinoma in situ involving a sclerosing lesion with adenosis: report of a case. Arch Pathol Lab Med; 2009 Nov;133(11):1817-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine ductal carcinoma in situ involving a sclerosing lesion with adenosis: report of a case.
  • Apocrine atypia is characterized by 3-fold nuclear enlargement, multiple nucleoli, and hyperchromatism and generally arises in florid adenosis or radial sclerosing lesions.
  • Herein, I report a case in which apocrine ductal carcinoma in situ presented as "atypical apocrine adenosis" in a needle core breast biopsy.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Fibrocystic Breast Disease / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886717.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Gnepp DR, Wang LJ, Brandwein-Gensler M, Slootweg P, Gill M, Hille J: Sclerosing polycystic adenosis of the salivary gland: a report of 16 cases. Am J Surg Pathol; 2006 Feb;30(2):154-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing polycystic adenosis of the salivary gland: a report of 16 cases.
  • Sclerosing polycystic adenosis is a recently described, extremely rare, reactive, sclerosing, inflammatory process somewhat similar to fibrocystic changes and adenosis tumor of the breast.

  • MedlinePlus Health Information. consumer health - Salivary Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434888.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Chen YB, Magpayo J, Rosen PP: Sclerosing adenosis in sentinel axillary lymph nodes from a patient with invasive ductal carcinoma: an unusual variant of benign glandular inclusions. Arch Pathol Lab Med; 2008 Sep;132(9):1439-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing adenosis in sentinel axillary lymph nodes from a patient with invasive ductal carcinoma: an unusual variant of benign glandular inclusions.
  • We report an exceptional instance in which a patient with invasive ductal carcinoma had benign glandular inclusions in the form of sclerosing adenosis in 2 sentinel lymph nodes.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788857.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


29. Fulciniti F, Losito NS, Ionna F, Longo F, Aversa C, Botti G, Foschini MP: Sclerosing polycystic adenosis of the parotid gland: report of one case diagnosed by fine-needle cytology with in situ malignant transformation. Diagn Cytopathol; 2010 May;38(5):368-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing polycystic adenosis of the parotid gland: report of one case diagnosed by fine-needle cytology with in situ malignant transformation.
  • Sclerosing polycystic adenosis (SPA) is a rare pathological condition affecting the salivary glands, first described by Smith etal. in 1996.
  • In line with numerous other pathological analogies between breast and salivary gland lesions, SPA shares with fibrocystic disease of the breast many histopathological features, i.e., fibrosis, oncocytic (apocrine) changes, hyperplasia of ductal and acinar epithelium, cystic dilation of ducts, and, often, atypical epithelial changes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19937766.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Skálová A, Gnepp DR, Simpson RH, Lewis JE, Janssen D, Sima R, Vanecek T, Di Palma S, Michal M: Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker. Am J Surg Pathol; 2006 Aug;30(8):939-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker.
  • Sclerosing polycystic adenosis (SPA) is a recently described, rare lesion of the salivary glands that bears a resemblance to epithelial proliferative lesions of the breast.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861963.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers, Tumor; 0 / Receptors, Androgen
  •  go-up   go-down


31. Li J, Yang SJ, Zhao XL, Zhang YQ, Li KN, Cui JH, Li J: [Significant increase of glucose transport activity in breast cancer]. Zhonghua Bing Li Xue Za Zhi; 2008 Feb;37(2):103-8
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significant increase of glucose transport activity in breast cancer].
  • OBJECTIVE: To study the expression level and significance of glucose transporter 1 (Glut-1) in normal breast tissue, adenosis, adenoma and breast carcinoma.
  • METHODS: A total of 147 cases of female breast tissue samples, including 92 cases of invasive ductal carcinoma, 26 cases of breast fibroadenoma, 24 cases of breast adenosis and 5 cases of normal breast tissues, were collected for quantitative detection of the expression of Glut-1 protein by immunohistochemistry (EnVision method) and Western blot, and its mRNA by reverse transcriptase-polymerase chain reaction (RT-PCR).
  • RESULTS: In normal breast tissue and benign lesions of the breast, Glut-1 was undetectable or only weakly detectable in cytoplasm of ductal and acinar epithelia.
  • Western blot and RT-PCR analyses showed that the expression of Glut-1 protein and mRNA were significantly increased in invasive ductal carcinoma than fibroadenoma (P =0.001 for protein; P <0.05 for mRNA) and adenosis (P =0.001 for protein; P < 0.05 for mRNA).
  • CONCLUSIONS: Glucose transport activity, as indicated by Glut-1 protein and its mRNA expression, significantly increases in breast carcinoma than non-cancerous lesions.
  • The over-expression of Glut-1 in breast carcinoma is tightly coupled with tumor cell proliferation, invasion and metastasis, implying that Glut-1 may serve as a new marker in the early diagnosis and prognostication of breast malignancy as well as a new therapeutic target.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Gene Expression Regulation, Neoplastic. Glucose / physiology. Glucose Transporter Type 1 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681321.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transport Proteins, Facilitative; 0 / Glucose Transporter Type 1; IY9XDZ35W2 / Glucose
  •  go-up   go-down


32. Kuroda N, Katto K, Ohtsuki Y, Hes O, Michal M, Inoue K, Ohara M, Mizuno K, Lee GH: Hybrid sclerosing adenosis and basal cell hyperplasia of the prostate. Med Mol Morphol; 2010 Dec;43(4):226-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid sclerosing adenosis and basal cell hyperplasia of the prostate.
  • Hybrid sclerosing adenosis and basal cell hyperplasia of the prostate is a rare lesion.
  • Histological examination of the transurethral resection of the prostate of a 83-year-old Japanese man showed a small lesion consisted of sclerosing adenosis and basal cell hyperplasia, in addition to the diffuse glandular and fibromuscular hyperplasia.
  • Immunohistochemically, many basal cells in sclerosing adenosis and basal cell hyperplasia areas showed a positive reaction for p63, cytokeratin 5, and D2-40.
  • Additionally, many basal cells in the sclerosing adenosis area and some basal cells in the basal cell hyperplasia area were positive for S-100 protein and alpha-smooth muscle actin, which are myoepithelial cell markers.
  • Finally, we suggest that hybrid sclerosing adenosis and basal cell hyperplasia may be actually a special form of hyperplastic lesion of all components of prostatic tissue, reflecting the unbalanced distribution of glandular, stromal (sclerosing adenosis), and basal cell hyperplasia with the differentiation toward myoepithelial cells predominantly occurring in a sclerosing adenosis area.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1989 Mar;14(3):317-9 [2707765.001]
  • [Cites] Med Mol Morphol. 2008 Jun;41(2):109-12 [18592165.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):660-7 [1711794.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jan;127(1):e14-6 [12562286.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(3):191-6 [1696762.001]
  • [Cites] Med Mol Morphol. 2010 Sep;43(3):165-9 [20857265.001]
  • [Cites] Arch Pathol Lab Med. 1987 Apr;111(4):363-6 [2435261.001]
  • [Cites] Histopathology. 2007 Nov;51(5):719-21 [17927601.001]
  • [Cites] Histopathology. 1992 Jun;20(6):505-10 [1376714.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):434-40 [11950918.001]
  • [Cites] Am J Surg Pathol. 1989 Oct;13(10):866-72 [2476945.001]
  • [Cites] Am J Surg Pathol. 1992 Apr;16(4):383-91 [1373581.001]
  • [Cites] Urology. 1983 Jan;21(1):88-9 [6823716.001]
  • [Cites] Am J Surg Pathol. 1991 Dec;15(12):1171-80 [1720930.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):737-47 [7793471.001]
  • [Cites] Am J Pathol. 1990 Apr;136(4):957-66 [1691595.001]
  • (PMID = 21267699.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Membrane Proteins; 0 / S100 Proteins; 0 / monoclonal antibody D2-40
  •  go-up   go-down


33. Georgiev D, Karag'ozov I, Velev M, Makaveeva V: [Three cases of vaginal adenosis after topical 5-fluorouracil therapy for vaginal HPV-associated lesions]. Akush Ginekol (Sofiia); 2006;45(3):59-61
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases of vaginal adenosis after topical 5-fluorouracil therapy for vaginal HPV-associated lesions].
  • Three cases of vaginal adenosis after topical 5-fluorouracil therapy for vaginal HPV-associated lesions are reported.
  • By colposcopic and histologic examinations vaginal adenosis was proved without histories of intrautering DES exposure.

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • MedlinePlus Health Information. consumer health - Vaginitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889191.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Bulgaria
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Cheng L, Bostwick DG: Atypical sclerosing adenosis of the prostate: a rare mimic of adenocarcinoma. Histopathology; 2010 Apr;56(5):627-31
MedlinePlus Health Information. consumer health - Prostate Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical sclerosing adenosis of the prostate: a rare mimic of adenocarcinoma.
  • AIMS: Sclerosing adenosis of the prostate is a benign, small, acinar proliferation in dense spindle cell stroma, with a distinct immunohistochemical profiles.
  • METHODS AND RESULTS: We describe five cases of sclerosing adenosis with significant cytological atypia, referred to as atypical sclerosing adenosis (ASA), which were initially considered suspicious or diagnostic of adenocarcinoma.
  • Seven other cases of typical sclerosing adenosis were used as controls.
  • All cases of typical and atypical sclerosing adenosis displayed an intact basal cell layer, which was immunoreactive for high-molecular-weight keratin, S100 protein, smooth muscle actin, and prostate-specific antigen, with no differences between ASA and the control group.
  • All cases of typical sclerosing adenosis were diploid.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459573.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Swelam WM: The pathogenic role of Epstein-Barr virus (EBV) in sclerosing polycystic adenosis. Pathol Res Pract; 2010 Aug 15;206(8):565-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathogenic role of Epstein-Barr virus (EBV) in sclerosing polycystic adenosis.
  • Sclerosing polycystic adenosis (SPA) is a pathology of the salivary gland which occurs infrequently and has a controversial etiology.

  • MedlinePlus Health Information. consumer health - Salivary Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20400234.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


36. Noonan VL, Kalmar JR, Allen CM, Gallagher GT, Kabani S: Sclerosing polycystic adenosis of minor salivary glands: report of three cases and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Oct;104(4):516-20
MedlinePlus Health Information. consumer health - Salivary Gland Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing polycystic adenosis of minor salivary glands: report of three cases and review of the literature.
  • Sclerosing polycystic adenosis (SPCA) of the salivary gland is a rarely encountered lesion of uncertain pathogenesis that shares histologic features with sclerosing adenosis and fibrocystic disease of the mammary gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17150380.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


37. Kloppenborg RP, Sepmeijer JW, Sie-Go DM, de Ru JA, Slootweg PJ: Sclerosing polycystic adenosis: a case report. B-ENT; 2006;2(4):189-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing polycystic adenosis: a case report.
  • Sclerosing Polycystic Adenosis (SPA) is a relatively unknown and newly described entity that is considered to be benign in nature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256407.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


38. Armah HB, Parwani AV: Atypical adenomatous hyperplasia (adenosis) of the prostate: a case report with review of the literature. Diagn Pathol; 2008;3:34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical adenomatous hyperplasia (adenosis) of the prostate: a case report with review of the literature.
  • Hence, the final histologic diagnosis was benign prostatic tissue with a focus of florid adenosis.
  • This case highlights the utility of these three immunostains (AMACR, p63 and CK903/34betaE12) in the accurate diagnosis of adenosis of the prostate on needle biopsy, and avoiding its misinterpretation as prostate adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2001 Jun;57(6):1117-20 [11377321.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):921-5 [12131160.001]
  • [Cites] Diagn Pathol. 2006;1:4 [16759347.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):967-71 [10487854.001]
  • [Cites] Urology. 1999 Feb;53(2):351-5 [9933053.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):389-91 [9458077.001]
  • [Cites] Pathologica. 1997 Jun;89(3):288-300 [9270265.001]
  • [Cites] Urology. 1995 Dec;46(6):837-42 [7502426.001]
  • [Cites] Virchows Arch. 1995;426(5):425-34 [7543337.001]
  • [Cites] Am J Surg Pathol. 1995 May;19(5):506-18 [7537024.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):737-47 [7793471.001]
  • [Cites] Am J Surg Pathol. 1994 Sep;18(9):863-70 [7520673.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;387(3):307-17 [7456316.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):148-58 [17170745.001]
  • (PMID = 18700013.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2526076
  •  go-up   go-down


39. Lotan TL, Epstein JI: Diffuse adenosis of the peripheral zone in prostate needle biopsy and prostatectomy specimens. Am J Surg Pathol; 2008 Sep;32(9):1360-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse adenosis of the peripheral zone in prostate needle biopsy and prostatectomy specimens.
  • It is unclear whether this architectural pattern, which we have termed diffuse adenosis of the peripheral zone (DAPZ), is simply a crowded glandular variant of normal prostate morphology or whether it represents a risk factor for the development of prostatic carcinoma.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670353.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


40. Vang R, Vinh TN, Burks RT, Barner R, Kurman RJ, Ronnett BM: Pseudoinfiltrative tubal metaplasia of the endocervix: a potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma. Int J Gynecol Pathol; 2005 Oct;24(4):391-8
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoinfiltrative tubal metaplasia of the endocervix: a potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma.
  • The clinicopathologic findings suggest the lesions are benign, and the association with in utero DES exposure raises the possibility that these could be a form of DES-related adenosis.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175088.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


41. Wang X, Zhao T, Zhao JJ, Xiong JB: [BRCA1 selectively regulates the expression of progesterone receptor A in sporadic invasive ductal breast carcinoma]. Zhonghua Yi Xue Za Zhi; 2010 May 25;90(20):1399-402
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BRCA1 selectively regulates the expression of progesterone receptor A in sporadic invasive ductal breast carcinoma].
  • OBJECTIVE: To investigate the expression level of BRCA1, progesterone receptor A (PRA) and B (PRB) in tissue of sporadic invasive ductal breast carcinoma and further statistically analyze the BRCA1 effects on the expression rates of PRA and PRB.
  • METHODS: Sixty-eight cases of adenosis of breast and sporadic invasive ductal breast carcinoma were selected.
  • Wilcoxon two-sample test was used to analyze the differential expression of BRCA1 between adenosis and sporadic invasive ductal breast carcinoma.
  • (1) In invasive sporadic ductal breast carcinoma, the positive rate of BRCA1 expression of 60.29% (41/68) was lower than the positive rate of BRCA1 expression at 85.30% (58/68) in adenosis of breast.
  • (2) In invasive sporadic ductal breast carcinoma, the positive rate of PRA expression for negative BRCA1 expression samples was 81.48% (22/27) and it was higher than the positive rate of PRA expression at 53.66% (22/47) for positive BRCA1 expression samples.
  • It indicated that the expression of BRCA1 affected the expression rate of PRA; In invasive sporadic ductal breast carcinoma, the PRB expression rates between positive and negative BRCA1 expression samples were not statistically significant (P > 0.05).
  • CONCLUSION: In sporadic breast carcinoma, a negative expression of BRCA1 is selectively associated with a higher expression rate of PRA rather than PRB.
  • Thus BRCA1 selectively regulates the expression of PRA in sporadic breast carcinoma.
  • [MeSH-major] BRCA1 Protein / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Receptors, Progesterone / metabolism


42. Bratthauer GL, Saenger JS, Strauss BL: Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation. Histopathology; 2005 Dec;47(6):611-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation.
  • AIMS: The nuclear detection of p63 in myoepithelial cells of the breast has been useful in identifying possibly invasive carcinomas.
  • The aim was to determine whether this reaction is specific for p63 and indicative of all breast secretory cells.
  • METHODS: Thirty breast specimens were tested immunohistochemically for p63 protein.
  • These included seven with benign secretory changes, 10 secretory carcinomas (nine invasive), one microglandular adenosis, three lobular neoplasias, four invasive ductal carcinomas, three clear cell carcinomas, one squamous cell carcinoma and one mucinous carcinoma.
  • The detection of p63 protein continues to have considerable value for the identification of myoepithelial cells and thus the determination of invasion, but will also have value in the determination of secretory carcinomas of the breast and in understanding their development.
  • [MeSH-major] Antibodies / metabolism. Breast / cytology. Breast / metabolism. Cell Differentiation. Genes, Tumor Suppressor. Phosphoproteins. Trans-Activators
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma / chemistry. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cytoplasm / metabolism. DNA-Binding Proteins. Epithelial Cells / cytology. Epithelial Cells / metabolism. Female. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Immunohistochemistry. Neoplasm Invasiveness. Transcription Factors. Tumor Suppressor Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324199.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


43. He Q, Fan X, Guan Y, Tian J, Fan Z, Zheng L: Percutaneous excisional biopsy of impalpable breast lesions under ultrasound visualization. Breast; 2008 Dec;17(6):666-70
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous excisional biopsy of impalpable breast lesions under ultrasound visualization.
  • Within the last ten years, the development of innovative minimally invasive breast biopsy technologies has made a significant impact on the diagnostic evaluation of impalpable breast lesions.
  • The minimally invasive biopsies for 143 impalpable breast lesions in 86 patients were performed using the B-ultrasound-guided 8-gauge vacuum-assisted Mammotome system at Jinan Military General Hospital.
  • One hundred and forty-three breast lesions in 86 patients were excised completely using this method.
  • One hundred and twenty-one lesions were diagnosed as fibroadenoma, nineteen lesions as breast adenosis, one lesion as invasive breast cancer, and two lesions as ductal carcinoma in situ.
  • The results suggest that the B-ultrasound-guided Mammotome system may be an efficient tool for the diagnosis and treatment of impalpable breast lesions.
  • [MeSH-major] Breast Diseases / pathology. Breast Diseases / ultrasonography
  • [MeSH-minor] Adult. Biopsy / instrumentation. Biopsy / methods. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Female. Fibroadenoma / pathology. Fibroadenoma / ultrasonography. Fibrocystic Breast Disease / pathology. Fibrocystic Breast Disease / ultrasonography. Humans. Middle Aged. Predictive Value of Tests. Ultrasonography, Mammary. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18835778.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


44. Ding JH, Peng WJ, Jiang ZX, Xu LH, Hu DT, Zheng XJ: [Diagnostic value of full-field digital mammography for breast carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Nov;31(11):854-7
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic value of full-field digital mammography for breast carcinoma].
  • OBJECTIVE: To evaluate the diagnostic value of full-field digital mammography for breast cancer.
  • METHODS: The clinical data and mammograms of 230 patients with breast diseases between January 2008 and July 2008 were collected and reviewed.
  • Three experienced radiologists in breast imaging assessment analyzed and classified all the mammograms according to breast imaging reporting and data system (BI-RADS).
  • RESULTS: Of the 238 samples, 130 had a malignant breast tumors and 108 cases of benign breast lesions.
  • One hundred and nine of the 130 malignant breast tumors were invasive ductal carcinoma.
  • Fifty-seven of the 108 benign breast lesions were breast adenosis.
  • The sensitivity, specificity and accuracy of FFDM in detecting breast carcinoma were 90.8%, 87.0% and 89.1%, respectively.
  • CONCLUSION: Full-field digital mammography (FFDM) is helpful in detection of breast cancers in women, with a higher sensitivity, specificity and accuracy, and has an important clinical application value.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibrocystic Breast Disease / diagnosis. Mammography / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Diseases / diagnosis. Breast Diseases / radiography. Calcinosis / diagnosis. Calcinosis / radiography. Diagnostic Errors. Female. Humans. Middle Aged. Radiographic Image Interpretation, Computer-Assisted. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137352.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


45. Bratthauer GL, Strauss BL, Barner R: Reversed Expression of the JAK/STAT Pathway Related Proteins Prolactin Receptor and STAT5a in Normal and Abnormal Breast Epithelial Cells. Breast Cancer (Auckl); 2008;1:7-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversed Expression of the JAK/STAT Pathway Related Proteins Prolactin Receptor and STAT5a in Normal and Abnormal Breast Epithelial Cells.
  • One component, STAT5a, is activated in the breast upon prolactin to prolactin receptor (PRLR) binding facilitating the transcription of genes involved in lobule development.
  • STAT5a was previously found to be expressed in most normal breast epithelial cells but not in many in situ or invasive carcinomas except secretory carcinomas which retain STAT5a expression.
  • This report examines the JAK/STAT pathway in the breast through the detection of PRLR and STAT5a.
  • Fifty breast tissues, including benign secretory change, microglandular adenosis, usual and atypical hyperplasia and in situ and invasive ductal carcinoma both usual and secretory, were obtained from the files of the Armed Forces Institute of Pathology.
  • PRLR was minimally detected on the surface of a few normal breast epithelial cells whereas STAT5a was greatly expressed in over 80% of normal cell nuclei.
  • However, the opposite pattern was seen in breast carcinomas lacking STAT5a expression.
  • This reversed expression may indicate a JAK/STAT pathway disturbance that could play a role in the initiation or maintenance of an abnormal breast phenotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mammary Gland Biol Neoplasia. 1999 Jan;4(1):79-88 [10219908.001]
  • [Cites] Endocrinology. 1997 Dec;138(12):5555-60 [9389544.001]
  • [Cites] Gynecol Obstet Invest. 1999;48(2):127-32 [10461005.001]
  • [Cites] Endocrinology. 1999 Dec;140(12):5659-68 [10579330.001]
  • [Cites] J Neuroimmunol. 2001 Nov 1;120(1-2):58-66 [11694320.001]
  • [Cites] J Clin Pathol. 2001 Dec;54(12):956-60 [11729217.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):367-76 [12450792.001]
  • [Cites] Mol Endocrinol. 2002 Dec;16(12):2675-91 [12456789.001]
  • [Cites] Dev Cell. 2002 Dec;3(6):877-87 [12479812.001]
  • [Cites] J Mol Endocrinol. 2003 Feb;30(1):31-47 [12580759.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):1-27 [12588805.001]
  • [Cites] J Cell Sci. 2004 Jan 15;117(Pt 2):271-80 [14676278.001]
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):665-71 [14696092.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Jan;88(1):69-77 [15026085.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2053-60 [15169792.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1449-60 [15509516.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13817-23 [15677474.001]
  • [Cites] Mol Endocrinol. 2005 Jul;19(7):1765-78 [15746191.001]
  • [Cites] Oncogene. 2006 Mar 23;25(13):1896-902 [16278670.001]
  • [Cites] Hum Pathol. 2006 May;37(5):586-92 [16647957.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):202-11 [9583737.001]
  • [Cites] Endocrine. 2000 Aug;13(1):37-46 [11051045.001]
  • [Cites] Mol Endocrinol. 2000 Dec;14(12):1986-2000 [11117529.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3826-32 [11502819.001]
  • [Cites] J Endocrinol. 2001 Oct;171(1):85-95 [11572793.001]
  • [Cites] J Cell Biol. 2001 Nov 12;155(4):531-42 [11706048.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):620-7 [12152161.001]
  • [Cites] Biochemistry. 2003 Jun 24;42(24):7561-70 [12809512.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52021-31 [14522994.001]
  • [Cites] Curr Med Res Opin. 2004 Apr;20(4):533-40 [15119991.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5510-20 [15169911.001]
  • [Cites] J Leukoc Biol. 1995 May;57(5):799-803 [7539031.001]
  • [Cites] Mol Endocrinol. 1995 Nov;9(11):1598-609 [8584036.001]
  • [Cites] Stem Cells. 1999;17(3):138-46 [10342556.001]
  • (PMID = 21655368.001).
  • [Journal-full-title] Breast cancer : basic and clinical research
  • [ISO-abbreviation] Breast Cancer (Auckl)
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3091403
  • [Keywords] NOTNLM ; STAT5a / breast / immunohistochemistry / prolactin receptor / secretory
  •  go-up   go-down


46. Mano MS, Kerr J, Kennedy J: Management of breast cancer in patients prenatally exposed to diethylstilbestrol: are we prepared? Breast; 2005 Oct;14(5):408-10
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of breast cancer in patients prenatally exposed to diethylstilbestrol: are we prepared?
  • The use of diethylstilbestrol (DES) for high risk pregnancy has exposed millions of mothers to an increased risk of breast cancer, and also resulted in a generation of women with genital tract abnormalities, such as vaginal adenosis.
  • It is still too early to say that exposure to DES will also result in an increased risk of breast cancer in the offspring, though there is some preliminary evidence to support this.
  • The employment of optimal hormonal therapy (for breast cancer) in this special population may be hampered by the fact that agents with oestrogen agonistic activity (such as tamoxifen) may be contraindicated.
  • Finally, the prevalence prenatal exposure to DES may have been underestimated patients diagnosed with breast cancer, though this information might have major implications in their management.
  • We report on the interesting example of a young woman with a history of vaginal adenosis, who was also diagnosed with early breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Diethylstilbestrol / adverse effects. Prenatal Exposure Delayed Effects. Vaginal Diseases / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216745.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


47. Croce S, Bretz-Grenier MF, Mathelin C: [Most common benign epithelial breast diseases: diagnosis, treatment and cancer risk]. Gynecol Obstet Fertil; 2008 Jul-Aug;36(7-8):788-99
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Most common benign epithelial breast diseases: diagnosis, treatment and cancer risk].
  • As a consequence of breast imaging development and increased interventional radiology, benign epithelial breast diseases (BEBD) represent a growing percentage of breast pathology diagnoses.
  • BEBD include numerous entities such as cysts, fibrosis, adenosis, duct ectasia, which require neither surgery nor follow-up.
  • Some BEBD have to be individualized (radial scars, papillomas, complex sclerosing adenosis, lobular intraepithelial neoplasia, flat epithelial atypia, atypical hyperplasia), being preinvasive lesions or markers of increased breast cancer risk, or being associated with suspect radiological aspect.
  • [MeSH-major] Breast Diseases / radiography. Breast Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650113.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 63
  •  go-up   go-down


48. Kaya H, Güllüoglu B, Aribal E: Myoepithelial differentiation in breast carcinoma. Tumori; 2008 Jan-Feb;94(1):116-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoepithelial differentiation in breast carcinoma.
  • BACKGROUND: The aim of presenting this work is to describe a matrix producing carcinoma with anaplastic myoepithelial cell foci, with the coexistence of in situ myoepithelial carcinoma which originated from a sclerosing adenosis.
  • CASE REPORT: A 51-year-old perimenopausal woman presented with a hard irregular lump in her left breast.
  • The tumor was composed of a sclerosed fibroadenoma and preexisting sclerosing adenosis with poorly differentiated overt carcinoma within the cartilaginous matrix.
  • [MeSH-major] Breast Neoplasms / pathology. Fibroadenoma / pathology. Myoepithelioma / pathology


49. Wells CA, El-Ayat GA: Non-operative breast pathology: apocrine lesions. J Clin Pathol; 2007 Dec;60(12):1313-20
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-operative breast pathology: apocrine lesions.
  • Apocrine metaplasia is a very common finding in the female breast after the age of 25.
  • It is so common that many people regard it as a normal component of the breast.
  • The apocrine cell does, however, contribute to a number of different breast lesions, some of which are very taxing diagnostically; apocrine variants of both in-situ and invasive cancer are encountered.
  • This review considers the common apocrine metaplastic lesions seen in fibrocystic change as well as apocrine adenoma, apocrine change within sclerosing adenosis, atypical apocrine lesions and apocrine malignancies.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenoma / pathology. Biopsy. Breast / pathology. Carcinoma, Ductal, Breast / pathology. Female. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / pathology. Metaplasia / pathology. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Nov;52(11):838-41 [10690175.001]
  • [Cites] APMIS. 2006 May;114(5):352-8 [16725011.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):207-14 [11141494.001]
  • [Cites] Hum Pathol. 2001 May;32(5):487-93 [11381366.001]
  • [Cites] Histopathology. 2001 Aug;39(2):198-202 [11493337.001]
  • [Cites] J Clin Pathol. 2002 Jan;55(1):14-6 [11825917.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):449-55 [12447674.001]
  • [Cites] Breast J. 2003 Jul-Aug;9(4):335-6 [12846876.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):703-11 [12910513.001]
  • [Cites] Adv Anat Pathol. 2004 Jan;11(1):1-9 [14676636.001]
  • [Cites] Cancer. 1968 Apr;21(4):756-63 [4296681.001]
  • [Cites] Cancer. 1976 Jun;37(6):2891-905 [949710.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2463-71 [6254632.001]
  • [Cites] Surg Gynecol Obstet. 1981 Apr;152(4):437-40 [7209771.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Am J Surg Pathol. 1983 Jul;7(5):451-61 [6351647.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Sep;21(9):1047-50 [4065177.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):532-41 [3717305.001]
  • [Cites] Ann N Y Acad Sci. 1986;464:262-74 [3524352.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):381-6 [3557440.001]
  • [Cites] Histopathology. 1987 Jun;11(6):603-10 [3305282.001]
  • [Cites] Histopathology. 1987 Mar;11(3):305-15 [2828217.001]
  • [Cites] Br J Cancer. 1987 Dec;56(6):814-9 [2829956.001]
  • [Cites] Breast Cancer Res Treat. 1988 Sep;12(1):37-44 [2848603.001]
  • [Cites] Hum Pathol. 1989 Mar;20(3):281-7 [2542151.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:161-73 [2192632.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:188-97 [2357000.001]
  • [Cites] Am J Clin Pathol. 1990 Oct;94(4):371-7 [2171320.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):687-94 [2058763.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):953-5 [1931623.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):655-62 [1592388.001]
  • [Cites] Cancer Detect Prev. 1992;16(2):99-106 [1600527.001]
  • [Cites] CMAJ. 1992 Jul 1;147(1):45-9 [1393887.001]
  • [Cites] N Engl J Med. 1994 Jul 7;331(1):10-5 [8202095.001]
  • [Cites] Cytopathology. 1994 Apr;5(2):123-8 [8038424.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2529-37 [8640702.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jan;5(1):29-32 [8770463.001]
  • [Cites] BMJ. 1997 Mar 29;314(7085):925-8 [9099114.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):967-73 [9269834.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1798-802 [9351550.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] Virchows Arch. 1998 Dec;433(6):505-9 [9870682.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] Lancet. 1999 May 22;353(9166):1742-5 [10347986.001]
  • [Cites] Breast. 2005 Feb;14(1):3-10 [15695074.001]
  • [Cites] Breast. 2005 Feb;14(1):37-41 [15695079.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] J Pathol. 2000 Jun;191(2):138-42 [10861572.001]
  • (PMID = 18042688.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 62
  • [Other-IDs] NLM/ PMC2095572
  •  go-up   go-down


50. Lopez-Beltran A, Qian J, Montironi R, Luque RJ, Bostwick DG: Atypical adenomatous hyperplasia (adenosis) of the prostate: DNA ploidy analysis and immunophenotype. Int J Surg Pathol; 2005 Apr;13(2):167-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical adenomatous hyperplasia (adenosis) of the prostate: DNA ploidy analysis and immunophenotype.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864380.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


51. Kondi-Pafiti A, Arkadopoulos N, Gennatas C, Michalaki V, Frangou-Plegmenou M, Chatzipantelis P: Expression of c-kit in common benign and malignant breast lesions. Tumori; 2010 Nov-Dec;96(6):978-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit in common benign and malignant breast lesions.
  • In recent years, the role of c-kit in the development of preinvasive and invasive breast carcinomas has been investigated.
  • The aim of our study was to detect c-kit expression in the entire spectrum of common benign and malignant breast lesions in correlation with a well-studied myoepithelial or stem-cell like marker (p63).
  • METHODS AND STUDY DESIGN: We evaluated 270 cases of benign and malignant breast lesions including fibrocystic disease, fibroadenoma, sclerosing adenosis, atypical ductal hyperplasia, ductal/lobular carcinoma in situ, and ductal/lobular/mixed type carcinoma.
  • RESULTS: c-kit was highly expressed (85.3%) in benign lesions (fibrocystic disease, sclerosing adenosis, fibroadenoma), and p63 expression was 95.5% in the aforementioned lesions. c-kit distribution in preinvasive and invasive lesions was as follows: ductal/lobular carcinoma in-situ, 43%/35%; ductal/lobular carcinoma, 36%/39%; and mixed type carcinoma, 20%.
  • CONCLUSIONS: Combined overexpression of c-kit and p63 is indicative of benign breast lesions.
  • In contrast, there is reduced expression of c-kit in in situ and invasive breast carcinomas, with simultaneous overexpression in the stromal cells.
  • This suggests that c-kit may play a role in breast cancer progression.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast / pathology. Breast Diseases / metabolism. Breast Diseases / pathology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Adult. Biomarkers / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Fibroadenoma / metabolism. Fibroblasts / metabolism. Fibrocystic Breast Disease / metabolism. Gene Expression Regulation, Neoplastic. Humans. Hyperplasia / metabolism. Immunohistochemistry. Membrane Proteins / metabolism. Sclerosis / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21388062.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


52. Laforga JB: A case of mucinous spherulosis of the breast diagnosed retrospectively in FNA material. Diagn Cytopathol; 2006 Sep;34(9):626-30
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of mucinous spherulosis of the breast diagnosed retrospectively in FNA material.
  • We describe for the first time the cytologic features of mucinous spherulosis (MS), a variant of collagenous spherulosis (CS) of the breast characterized by cribiform structures containing lightly basophilic material, embedded in a loosely mucinous acellular background.
  • Histologically, the lesion was part of a complex hyperplasia containing foci of sclerosing adenosis, and foci of atypical ductal hyperplasia (ADH).
  • [MeSH-major] Biopsy, Fine-Needle. Breast / pathology. Breast Diseases / pathology. Mucins / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adult. Breast Neoplasms / pathology. Collagen / metabolism. Diagnosis, Differential. Female. Fibrocystic Breast Disease / complications. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / complications. Hyperplasia / metabolism. Hyperplasia / pathology. Mammary Glands, Human / metabolism. Mammary Glands, Human / pathology. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16900477.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins; 9007-34-5 / Collagen
  •  go-up   go-down


53. Brujan I, Mărgăritescu C, Simionescu C, Pirici D, Fronie A, Foarfă C, Stepan A, Vrabete M: Cathepsin-D expression in breast lesion: an immunohistochemical study. Rom J Morphol Embryol; 2009;50(1):31-9
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsin-D expression in breast lesion: an immunohistochemical study.
  • The aim of our study was to compare the expression of CathD in most common breast tumors and tumor-like breast lesions.
  • The study includes 21 patients with histologically verified breast lesions (adenosis, ductal hyperplasia, fibroadenomas, and different types of invasive carcinoma).
  • We investigated the cathepsin-D expression in these breast lesions using immunohistochemistry (IH; paraffin-embedded tissues).
  • The immunostaining was more obvious in breast invasive carcinomas and macrophages.
  • Adenosis had the maximum area/signal intensity from all studied breast benign lesions (p<0.001, Student t-test).
  • These results suggest that CathD expression was strongest in malignant than in benign breast disease, the positivity being present in both epithelial neoplastic and stromal cells.
  • [MeSH-major] Breast Diseases / enzymology. Breast Neoplasms / enzymology. Carcinoma, Ductal, Breast / enzymology. Cathepsin D / metabolism
  • [MeSH-minor] Breast / enzymology. Breast / pathology. Carcinoma / enzymology. Carcinoma / pathology. Female. Fibrocystic Breast Disease / enzymology. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / enzymology. Immunohistochemistry. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19221643.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


54. Pojchamarnwiputh S, Muttarak M, Na-Chiangmai W, Chaiwun B: Benign breast lesions mimicking carcinoma at mammography. Singapore Med J; 2007 Oct;48(10):958-68
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign breast lesions mimicking carcinoma at mammography.
  • Many benign breast lesions pose diagnostic challenges.
  • These lesions include abscess, haematoma, radial scar, post surgical scar, diabetic mastopathy, focal fibrosis, sclerosing adenosis, granular cell tumour, extra-abdominal desmoid tumour, medial insertion of pectoralis muscle and sternalis muscle, and axillary lymphadenopathy (due to HIV infection, collagen vascular lesions, tuberculous and bacterial lymphadenitis).
  • [MeSH-major] Breast Diseases. Mammography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Biopsy, Needle. Breast Neoplasms / pathology. Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography. Carcinoma / pathology. Carcinoma / radiography. Carcinoma / ultrasonography. Diagnosis, Differential. Female. Histocytochemistry. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909685.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


55. Zizi-Sermpetzoglou A, Vasilakaki T, Grammatoglou X, Petrakopoulou N, Nikolaidou ME, Glava C: Malignant adenomyoepithelioma of the breast--case report. Eur J Gynaecol Oncol; 2009;30(2):234-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant adenomyoepithelioma of the breast--case report.
  • Malignant adenomyoepithelioma (MAME) of the breast is a rare tumor characterized on the basis of histologic, immunohistochemical and ultrastructural features by malignant proliferation of the epithelial and myoepithelial cells.
  • We report a case of an 80-year-old woman with malignant adenomyoepithelioma of the breast, one of the oldest patients described up to today.
  • A primary tumor in the left breast grew within a short period of time.
  • The tumor was associated with adenosis and in adjacent positions to the infiltrating portions a circumscribed nodule with histological features of benign adenomyoepithelioma was present.
  • [MeSH-major] Adenomyoepithelioma. Breast Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480267.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


56. Niu Y, Fu XL, Yu Y, Wang PP, Cao XC: Intra-operative frozen section diagnosis of breast lesions: a retrospective analysis of 13,243 Chinese patients. Chin Med J (Engl); 2007 Apr 20;120(8):630-5
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-operative frozen section diagnosis of breast lesions: a retrospective analysis of 13,243 Chinese patients.
  • BACKGROUND: Although cytological methods for breast oncology have been used in recent decades, intra-operative frozen section has been playing a vital role in making therapeutic decisions.
  • We analyzed a large series of frozen section diagnoses for Chinese cases of breast lesion within the last 15 years.
  • The experience was expected to increase the diagnostic accuracy of cases with breast lesions.
  • METHODS: The data from consecutive 13243 cases of breast lesions diagnosed with intra-operative frozen sections between 1988 to 2002 were compared with paraffin sections in a case by case manner.
  • Six types (false invasion, peri-papilloma, adenoma of nipple duct, florid adenosis, sclerosing adenosis, and granulose cell tumor) of lesions may lead to false positive, and four types (morphological changes responding chemotherapy, well differentiated papillary carcinoma, invasive lobular carcinoma, and tubular carcinoma) to a false negative.
  • Gross and microscopic findings may be inconsistent in two types of lesions (radial scar and florid adenosis) microscopic and clinical findings in three types (ganulomatous mastitis mammary, duct ectasia, and fat necrosis), and three types (abundant fat or sclerous tissues; borderline lesions and changes of post-chemotherapy) were likely wrongly classified.
  • CONCLUSIONS: Intra-operative frozen section can accurately identify breast lesions in many instances, leading to fewer errors on account of more diagnostic experience and understanding of diagnostic limitations.
  • [MeSH-major] Breast Diseases / diagnosis. Breast Neoplasms / diagnosis. Frozen Sections / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Biopsy / methods. Breast / pathology. Child. China. Female. Humans. Intraoperative Care / methods. Male. Middle Aged. Paraffin Embedding / methods. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17517175.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


57. Tse GM, Tan PH, Pang AL, Tang AP, Cheung HS: Calcification in breast lesions: pathologists' perspective. J Clin Pathol; 2008 Feb;61(2):145-51
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcification in breast lesions: pathologists' perspective.
  • Evaluation of calcification in breast lesions is a major assessment criterion for breast mammography.
  • Fibroadenoma may be associated with large popcorn like calcifications, and sclerosing adenosis may have fine, punctate or granular calcifications.
  • [MeSH-major] Breast Neoplasms / radiography. Calcinosis / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704264.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


58. Berois N, Mazal D, Ubillos L, Trajtenberg F, Nicolas A, Sastre-Garau X, Magdelenat H, Osinaga E: UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker. J Histochem Cytochem; 2006 Mar;54(3):317-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker.
  • Considering that we recently found the ppGalNAc-T6 mRNA expressed in breast carcinomas, we produced a highly specific monoclonal antibody (MAb T6.3) to assess the expression profile of ppGalNAc-T6 protein product in breast tissues.
  • The expression of ppGalNAc-T6 by breast carcinoma cells was confirmed on MCF-7 and T47D cell lines.
  • In formalin-fixed tissues, ppGalNAc-T6 expression was observed in 60/74 (81%) breast cancers, 21/23 (91.3%) adjacent ductal carcinoma in situ (DCIS), 4/20 benign breast lesions (2/2 sclerosing adenosis and 2/13 fibroadenoma), and in 0/5 normal breast samples.
  • This fact, as well as the observation that ppGalNAc-T6 was strongly expressed in sclerosing adenosis and in most DCIS, suggests that ppGalNAc-T6 expression could be an early event during human breast carcinogenesis.
  • Considering that an abnormal O-glycosylation greatly contributes to the phenotype and biology of breast cancer cells, ppGalNAc-T6 expression could provide new insights about breast cancer glycobiology.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / enzymology. N-Acetylgalactosaminyltransferases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antibodies, Monoclonal. Breast Diseases / enzymology. Carcinoma, Ductal, Breast / enzymology. Carcinoma, Lobular / enzymology. Carcinoma, Papillary / enzymology. Female. Humans. Immunohistochemistry. Mammary Glands, Human / enzymology. Metaplasia. Mice. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16260590.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 2.4.1.- / N-Acetylgalactosaminyltransferases; EC 2.4.1.- / UDP-N-acetylgalactosamine polypeptide N-acetylgalactosaminyltransferase 6
  •  go-up   go-down


59. Liedtke C, Kersting C, Bürger H, Kiesel L, Wülfing P: Caveolin-1 expression in benign and malignant lesions of the breast. World J Surg Oncol; 2007;5:110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 expression in benign and malignant lesions of the breast.
  • We examined the potential clinical relevance of Caveolin-1 in normal, benign and malignant breast tissue specimens.
  • METHODS: Using tissue microarray (TMA) technology cases of invasive breast cancer, DCIS, benign breast disease (i.e. fibroadenoma, sclerosing adenosis, ductal hyperplasia and radial scar) and normal breast tissue were evaluated for Caveolin-1 expression.
  • RESULTS: No Caveolin-1 expression was observed in epithelial cells of normal breast tissue (n = 5), benign breast disease (n = 295) and DCIS (n = 108).
  • However, Caveolin-1 expression was found in 32 of 109 cases of invasive breast carcinomas (29.4%).
  • Caveolin-1 expression in invasive breast cancer could neither be correlated with survival parameters such as overall or disease-free survival nor with established clinical and pathological markers.
  • CONCLUSION: In this study we demonstrated expression of Caveolin-1 in one third of invasive breast cancers.
  • A significant increase in Caveolin-1 expression was observed comparing invasive breast cancer to both benign breast tissue and non-invasive breast cancer.
  • Since inhibitors of Caveolin-1 signalling are available, targeting Caveolin-1 in breast cancer may represent a potential option for future breast cancer treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Mar 11;18(10):1881-90 [10086342.001]
  • [Cites] Biochim Biophys Acta. 2000 Dec 15;1529(1-3):210-22 [11111090.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):90-101 [17200343.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):585-90 [16461571.001]
  • [Cites] Oncogene. 2006 Dec 14;25(59):7723-39 [16799639.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(1):85-90 [16541313.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):20448-55 [9685399.001]
  • [Cites] J Biol Chem. 1996 Apr 19;271(16):9690-7 [8621645.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1381-5 [7877987.001]
  • [Cites] J Biol Chem. 1989 Dec 5;264(34):20163-6 [2479645.001]
  • [Cites] Oncogene. 2002 Apr 4;21(15):2365-75 [11948420.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jul;129(7):375-82 [12884024.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1909-13 [14612902.001]
  • [Cites] Leuk Res. 2004 Sep;28(9):907-8 [15234566.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51630-46 [15355971.001]
  • [Cites] J Biol Chem. 1995 Jun 30;270(26):15693-701 [7797570.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):167-80 [7831528.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12155-8 [7991599.001]
  • [Cites] J Biol Chem. 1997 Oct 10;272(41):25437-40 [9325253.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1873-80 [9717814.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5719-23 [10582690.001]
  • [Cites] Science. 2001 Nov 30;294(5548):1862-5 [11729300.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4272-9 [11751529.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1140-4 [12402154.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4125-31 [14519635.001]
  • [Cites] Lung Cancer. 2003 Nov;42(2):195-202 [14568687.001]
  • [Cites] Trends Cell Biol. 1994 Jul;4(7):231-5 [14731661.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):959-65 [15305200.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1720-8 [15841074.001]
  • [Cites] Breast Cancer Res Treat. 2006 Feb;95(3):219-28 [16244790.001]
  • (PMID = 17915016.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2082377
  •  go-up   go-down


60. de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, de Almeida Matsura M, Alvarenga M, Vassallo J: p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast? Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):71-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast?
  • The immunohistochemical detection of myoepithelial cells in benign sclerosing lesions of the breast is useful in distinguishing them from tubular carcinoma.
  • The authors assessed the use of p63 and CD10 in the differential diagnosis between benign sclerosing lesions, such as sclerosing adenosis and radial scar, and tubular carcinoma, in comparison to the traditional myoepithelial markers 1A4 and calponin. p63, CD10, 1A4, and calponin were expressed in myoepithelial cells of all benign lesions and were consistently negative in all cases of tubular carcinoma.
  • In conclusion, p63 and CD10 may be used as a complement to 1A4 in distinguishing benign sclerosing lesions from tubular carcinoma of the breast.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540734.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


61. Petersson F, Tan PH, Putti TC: Low-grade ductal carcinoma in situ and invasive mammary carcinoma with columnar cell morphology arising in a complex fibroadenoma in continuity with columnar cell change and flat epithelial atypia. Int J Surg Pathol; 2010 Oct;18(5):352-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the clinicopathologic features of a small low-grade invasive mammary carcinoma with cytomorphological columnar cell features arising in a complex fibroadenoma that in addition to sclerosing adenosis, apocrine metaplasia, and usual ductal hyperplasia also displayed columnar cell change with flat epithelial atypia and low-grade ductal carcinoma in situ merging with the invasive carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Fibroadenoma / pathology. Neoplasms, Second Primary / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20643672.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


62. Cîmpean AM, Raica M, Nariţa D: Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast. Rom J Morphol Embryol; 2005;46(2):123-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast.
  • METHODS: Our study included 112 female patients with suspect breast masses obtained by surgery or biopsy.
  • RESULTS: We have found normal breast tissue, sclerosing adenosis, fibroadenomas, fibrocystic diseases, phyllodes tumor, DCIS, ductal invasive, lobular, squamous, medullary, mucinous, and papillary carcinomas.
  • All the normal breast tissues and most of benign lesions were positive for CD34 and negative for SMA.
  • [MeSH-major] Actins / analysis. Antigens, CD34 / analysis. Breast Neoplasms / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Biopsy. Carcinoma, Ductal / pathology. Female. Fibrocystic Breast Disease / pathology. Humans. Middle Aged. Neoplasm Invasiveness. Smad Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286998.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Smad Proteins
  •  go-up   go-down


63. Turashvili G, Hayes M, Gilks B, Watson P, Aparicio S: Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer? Virchows Arch; 2008 Jun;452(6):589-98
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer?
  • Columnar cell lesions (CCLs) are one of the most common abnormalities in the adult female human breast, characterized by the presence of columnar-shaped epithelial cells lining enlarged terminal-duct lobular units.
  • Columnar cell-like lesions have been described under a variety of names such as blunt duct adenosis, flat epithelial atypia, and ductal intraepithelial neoplasia type DIN1a.
  • [MeSH-major] Breast Neoplasms / pathology. Epithelial Cells / pathology. Mammary Glands, Human / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2007 Jun;50(7):859-65 [17543075.001]
  • [Cites] Ann Surg. 1945 Feb;121(2):197-222 [17858563.001]
  • [Cites] Rofo. 1981 Mar;134(3):225-31 [6260608.001]
  • [Cites] Breast Cancer Res. 2006;8(1):R6 [16417654.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2263-71 [11304780.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):223-35 [7831534.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92 (14 ):1126-35 [10904085.001]
  • [Cites] J Radiol. 2006 Nov;87(11 Pt 1):1671-7 [17095961.001]
  • [Cites] Histopathology. 2008 Jan;52(1):11-9 [18171413.001]
  • [Cites] Breast Cancer. 2000;7(4):326-31 [11114859.001]
  • [Cites] Am J Clin Pathol. 1997 May;107(5):561-6 [9128269.001]
  • [Cites] Ann Pathol. 2003 Dec;23(6):582-92 [15094596.001]
  • [Cites] Virchows Arch. 2007 Nov;451(5):883-91 [17786469.001]
  • [Cites] Ann Pathol. 2003 Dec;23 (6):593-6 [15094597.001]
  • [Cites] Breast. 2005 Dec;14(6):487-92 [16169223.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):154-60 [12591968.001]
  • [Cites] Pathol Int. 2004 Aug;54(8):595-602 [15260850.001]
  • [Cites] Am J Surg. 2004 Oct;188(4):395-8 [15474433.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1521-7 [9850178.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1561 [10584711.001]
  • [Cites] Am J Clin Pathol. 2007 Dec;128(6):1023-34 [18024329.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1095-110 [12218567.001]
  • [Cites] Pathology. 2007 Apr;39(2):208-16 [17454750.001]
  • [Cites] Virchows Arch. 2007 Jul;451(1):1-10 [17551752.001]
  • [Cites] Bull Cancer. 2004 Dec 1;91 Suppl 4:S205-10 [15899609.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):172-9 [16424892.001]
  • [Cites] Virchows Arch. 2001 Mar;438(3):221-7 [11315617.001]
  • [Cites] J Br Menopause Soc. 2006 Dec;12 (4):186-93 [17178021.001]
  • [Cites] Pathologe. 2006 Sep;27(5):381-6 [16858557.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1866-72 [16452249.001]
  • [Cites] Virchows Arch. 2006 Dec;449(6):617-21 [17024423.001]
  • [Cites] Breast J. 2005 Sep-Oct;11(5):326-32 [16174153.001]
  • [Cites] Semin Diagn Pathol. 2004 Feb;21(1):18-24 [15074555.001]
  • [Cites] Int J Surg Pathol. 2007 Oct;15(4):369-75 [17913943.001]
  • [Cites] J Obstet Gynaecol Res. 2006 Jun;32(3):305-8 [16764621.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(5):375-80 [8100656.001]
  • [Cites] Mod Pathol. 2007 Nov;20(11):1149-55 [17767135.001]
  • [Cites] Semin Diagn Pathol. 1989 May;6(2):165-73 [2548274.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):252-62 [17591970.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):344-9 [16400324.001]
  • [Cites] Radiol Clin North Am. 2004 Sep;42(5):935-46, vii [15337426.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):417-26 [17325484.001]
  • [Cites] Histopathology. 2004 Apr;44(4):401-3 [15049911.001]
  • [Cites] Virchows Arch. 2001 Oct;439(4):523-30 [11710639.001]
  • [Cites] Breast J. 2005 May-Jun;11(3):210 [15871708.001]
  • [Cites] Pathology. 2005 Apr;37(2):105-11 [16028837.001]
  • [Cites] Eur J Radiol. 2006 Nov;60(2):264-9 [16891081.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1307-12 [17182657.001]
  • [Cites] Radiol Clin North Am. 2004 Sep;42(5):821-30, v [15337418.001]
  • [Cites] Int J Surg Pathol. 2001 Jul;9(3):201-6 [11584316.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):105-8 [15613861.001]
  • [Cites] Breast Cancer. 2003;10(4):294-300 [14634506.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):705-9 [15976336.001]
  • [Cites] Histopathology. 2000 Sep;37(3):232-40 [10971699.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):284-92 [17084437.001]
  • [Cites] Diagn Gynecol Obstet. 1980 Spring;2(1):67-70 [7472146.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):227-36 [17229950.001]
  • [Cites] Cancer. 2000 May 1;88(9):2072-81 [10813719.001]
  • [Cites] Annu Rev Public Health. 1998;19:101-23 [9611614.001]
  • [Cites] Breast Cancer Res. 2003;5(5):263-8 [12927037.001]
  • [Cites] Major Probl Pathol. 1979;11:i-xvi, 1-466 [547120.001]
  • [Cites] Breast J. 2005 Mar-Apr;11(2):140-2 [15730461.001]
  • [Cites] Obstet Gynecol Clin North Am. 2002 Mar;29(1):159-72 [11892864.001]
  • [Cites] Hum Pathol. 2007 Dec;38(12):1736-43 [17714759.001]
  • [Cites] Histol Histopathol. 2004 Apr;19(2):457-63 [15024706.001]
  • [Cites] Maturitas. 2001 Feb 28;38(1):103-13; discussion 113-6 [11311599.001]
  • (PMID = 18437416.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / Receptors, Androgen; 0 / Receptors, Progesterone
  • [Number-of-references] 79
  •  go-up   go-down


64. Hilson JB, Schnitt SJ, Collins LC: Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast. Am J Surg Pathol; 2010 Jun;34(6):896-900
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast.
  • Myoepithelial cells are also present around entrapped glandular spaces in benign sclerosing lesions of the breast, but the immunophenotype of these myoepithelial cells has not been characterized.
  • When compared with normal breast ducts and lobules on the same slide, myoepithelial cells associated with benign sclerosing lesions showed reduced expression of cytokeratin 5/6 in 31.8% of cases, smooth muscle myosin heavy chain in 20.9%, CD10 in 15.2%, p63 in 9.3%, and calponin in 6.4%.
  • The proportion of radial scars/complex sclerosing lesions and sclerosing adenosis with reduced expression was significantly different for CD10 (26.9% and 0% respectively; P=0.01) and p63 (17.4% and 0% respectively; P=0.05).
  • We conclude that myoepithelial cells associated with benign sclerosing lesions of the breast may show immunophenotypic differences from normal myoepithelial cells.
  • This needs to be taken into consideration when selecting myoepithelial markers to help distinguish benign sclerosing lesions from invasive breast cancer.
  • [MeSH-major] Breast Diseases / metabolism. Epithelial Cells / metabolism. Myocytes, Smooth Muscle / metabolism

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20463570.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


65. Ben Hassouna J, Damak T, Ben Slama A, Chargui R, Ben Dhiab T, Khomsi F, Gamoud A, Boussen H, Rahal K: Breast carcinoma arising within fibroadenomas. Report of four observations. Tunis Med; 2007 Oct;85(10):891-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma arising within fibroadenomas. Report of four observations.
  • BACKGROUND: Fibroadenoma is a frequent benign breast tumor affecting young woman.
  • AIM: The purpose of this study was to evaluate the outcome of patients with breast carcinoma arising within adenofibroma and to determine the clinical characteristics and the prognosis of this rare entity.
  • In two cases, fibroadenomas was complex, containing cysts, adenosis and apocrine metaplasia.
  • [MeSH-major] Adenofibroma / pathology. Breast Neoplasms / pathology. Carcinoma / pathology. Cell Transformation, Neoplastic / pathology
  • [MeSH-minor] Adult. Breast Cyst / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy. Metaplasia. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236815.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


66. Vamre TB, Stalsberg H, Thomas DB, WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Extra-tumoral breast tissue in breast cancer patients: variations with steroid contraceptive use. Int J Cancer; 2006 Jun 1;118(11):2827-31
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-tumoral breast tissue in breast cancer patients: variations with steroid contraceptive use.
  • The association between oral contraceptive (OC) use and benign breast changes in extra-tumoral breast tissue was studied histologically in 1,503 breast cancer patients from The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
  • The occurrence of ductal hyperplasia, ductal atypia, sclerosing adenosis, cysts, apocrine metaplasia, apocrine hyperplasia, apocrine atypia, adenosis, lobular atypia, duct ectasia, calcifications, inflammatory reaction, lactational metaplasia and a high epithelial-stromal ratio was graded semi-quantitatively.
  • Our results show that the effects of OC use on ductal hyperplasia in non-neoplastic breast tissue of breast cancer patients are similar to what others have found in patients with benign breast disease only.
  • The increased prevalence of extra-tumoral ductal carcinoma in situ in breast cancer patients who started OC use at high age may possibly be explained by a longer preinvasive phase in these patients.
  • [MeSH-major] Breast Diseases / etiology. Breast Neoplasms / complications. Carcinoma, Intraductal, Noninfiltrating / etiology. Contraceptives, Oral / adverse effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16380999.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCIPC CDC HHS / CE / NICHD-CE-84-16
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral
  •  go-up   go-down


67. Kurz KD, Steinhaus D, Klar V, Cohnen M, Wittsack HJ, Saleh A, Mödder U, Blondin D: Assessment of three different software systems in the evaluation of dynamic MRI of the breast. Eur J Radiol; 2009 Feb;69(2):300-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of three different software systems in the evaluation of dynamic MRI of the breast.
  • OBJECTIVE: The aim was to compare the diagnostic performance and handling of dynamic contrast-enhanced MRI of the breast with two commercial software solutions ("CADstream" and "3TP") and one self-developed software system ("Mammatool").
  • MATERIALS AND METHODS: Identical data sets of dynamic breast MRI from 21 patients were evaluated retrospectively with all three software systems.
  • RESULTS: There were 9 invasive carcinomas, one pure DCIS, one papilloma, one radial scar, three histologically proven changes due to mastopathy, one adenosis and two fibroadenomas.
  • Additionally two patients with enhancing parenchyma followed with MRI for more than 3 years and one scar after breast conserving therapy were included.
  • CONCLUSION: All three software programs tested were adequate for sensitive and efficient assessment of dynamic MRI of the breast.
  • [MeSH-major] Algorithms. Breast / pathology. Breast Neoplasms / diagnosis. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Software. Software Validation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060715.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


68. Ashbeck EL, Rosenberg RD, Stauber PM, Key CR: Benign breast biopsy diagnosis and subsequent risk of breast cancer. Cancer Epidemiol Biomarkers Prev; 2007 Mar;16(3):467-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign breast biopsy diagnosis and subsequent risk of breast cancer.
  • BACKGROUND: We examine benign breast biopsy diagnoses as reported by community pathologists in New Mexico and investigate associations with future breast cancer development.
  • METHODS: Using data collected between 1992 and 2000 by the New Mexico Mammography Project and cancer data through 2003 from the New Mexico Tumor Registry, we calculated breast cancer rates following 14,602 benign breast biopsies for women ages 30 to 89 years.
  • For comparison, we also calculated the breast cancer rate following 215,283 normal screening mammograms.
  • RESULTS: We identified 480 subsequent breast cancer diagnoses among 14,602 women with benign breast biopsies and 4,402 breast cancer diagnoses among 215,283 women with mammograms assigned a "negative" or "benign finding" assessment.
  • Among low-risk histologic diagnoses, the strongest associations with subsequent breast cancer development included adenosis, apocrine metaplasia, calcifications, and ductal hyperplasia.
  • Fibroadenoma, inflammation, and cysts did not exhibit an association with breast cancer development.
  • Women with low-risk diagnoses and breast tissue characterized as fatty or with scattered densities had a HR of 2.09 (95% CI, 1.68-2.60), whereas women with low-risk histologic diagnoses and dense breasts had a HR of 3.36 (95% CI, 2.83-3.99).
  • CONCLUSIONS: The observed breast cancer occurrence contributes to evidence of increased risk following benign biopsy.
  • The risk associated with histologic diagnoses in absence of atypia was twice the risk experienced by women with normal mammogram evaluations and may be modified by breast density.
  • [MeSH-major] Breast Diseases / pathology. Breast Neoplasms / pathology. Risk

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337650.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 U01 CA69976
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


69. Eliahou R, Sella T, Allweis T, Samet Y, Libson E, Sklair-Levy M: Magnetic resonance-guided interventional procedures of the breast: initial experience. Isr Med Assoc J; 2009 May;11(5):275-9
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance-guided interventional procedures of the breast: initial experience.
  • BACKGROUND: Magnetic resonance imaging of the breast has emerged as a valuable imaging tool in addition to conventional imaging modalities.
  • OBJECTIVES: To evaluate our initial clinical experience with MR-guided core needle breast biopsy and MR-guided needle localization.
  • Other benign findings were sclerosing adenosis, pseudoangiomatous stromal hyperplasia, fat necrosis, intraductal papilloma, fibroadenoma, capillary hemangioma, and florid ductal hyperplasia.
  • CONCLUSIONS: MR-guided interventional procedures of the breast are accurate, safe and feasible methods for sampling breast lesions detected only by MR and have become a significant tool in the management of certain patients.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Biopsy, Needle / methods. Breast Diseases / diagnosis. Breast Diseases / pathology. Breast Diseases / ultrasonography. Female. Gadolinium. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637504.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


70. Manfrin E, Mariotto R, Remo A, Reghellin D, Falsirollo F, Dalfior D, Bricolo P, Piazzola E, Bonetti F: Benign breast lesions at risk of developing cancer--a challenging problem in breast cancer screening programs: five years' experience of the Breast Cancer Screening Program in Verona (1999-2004). Cancer; 2009 Feb 1;115(3):499-507
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign breast lesions at risk of developing cancer--a challenging problem in breast cancer screening programs: five years' experience of the Breast Cancer Screening Program in Verona (1999-2004).
  • BACKGROUND: Cytology and core-needle biopsies are not always sufficient to exclude malignancy in benign breast lesions (BBL) that are at risk of developing cancer, and open biopsy often is mandatory.
  • The authors of this report evaluated the impact of the screen-detected BBL at risk of developing cancer that were counted in the quota of benign breast open biopsies in the Breast Cancer Screening Program of Verona.
  • METHODS: Benign open biopsies were subdivided into 4 groups according to their risk of developing cancer: Histo1, normal histology; Histo2, 'pure' BBL (fibroadenoma, fibrocystic disease, mastitis, adenosis); Histo3, BBL with a low risk of developing cancer (radial scar, papilloma, papillomatosis, phyllodes tumor, mucocele-like lesion); and Histo4, BBL with a high risk of developing cancer (atypical columnar cell hyperplasia, atypical ductal hyperplasia, atypical lobular hyperplasia).
  • [MeSH-major] Biopsy / methods. Breast Diseases / complications. Breast Neoplasms / diagnosis


71. Guinebretière JM, Menet E, Tardivon A, Cherel P, Vanel D: Normal and pathological breast, the histological basis. Eur J Radiol; 2005 Apr;54(1):6-14
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Normal and pathological breast, the histological basis.
  • Breast tissue is heterogeneous, associating connective and glandular structures, which grow and change cyclically under hormonal regulation.
  • Hormones are also thought to be the main determinant of the major benign and malignant pathologies encountered in the breast.
  • They usually associate different entities, (adenosis, fibrosis, cysts and hyperplasia) but vary in intensity and extension.
  • [MeSH-major] Breast / pathology. Breast / ultrastructure. Breast Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797289.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 22
  •  go-up   go-down


72. Chen JH, Nalcioglu O, Su MY: Fibrocystic change of the breast presenting as a focal lesion mimicking breast cancer in MR imaging. J Magn Reson Imaging; 2008 Dec;28(6):1499-505
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrocystic change of the breast presenting as a focal lesion mimicking breast cancer in MR imaging.
  • Focal fibrocystic change (FCC) of the breast is a rare form of FCC.
  • Breast sonography suspected malignancy in seven patients (7/10, 70%).
  • In pathology, all 11 patients showed the typical pathological features of fibrocystic change, with mixed components of stromal fibrosis, cyst formation, apocrine metaplasia, adenosis, and/or focal sclerosing adenosis.
  • In conclusion, MR imaging features of focal FCC usually present as a mass or focus lesion with rapid enhancement and washout kinetics that mimic a malignant breast lesion and lead to unnecessary operation, especially in patients with contralateral malignant breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):31-4 [10882242.001]
  • [Cites] Invest Radiol. 2005 Jul;40(7):436-41 [15973135.001]
  • [Cites] AJR Am J Roentgenol. 2006 Feb;186(2):426-30 [16423948.001]
  • [Cites] J Magn Reson Imaging. 2006 Apr;23(4):486-92 [16521096.001]
  • [Cites] J Magn Reson Imaging. 2007 Jan;25(1):104-12 [17152054.001]
  • [Cites] Curr Probl Diagn Radiol. 2007 Mar-Apr;36(2):66-82 [17331838.001]
  • [Cites] N Engl J Med. 2007 Mar 29;356(13):1295-303 [17392300.001]
  • [Cites] N Engl J Med. 1982 Oct 14;307(16):1010-4 [7110289.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Radiology. 1989 Mar;170(3 Pt 1):681-6 [2916021.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1375-9 [9574619.001]
  • [Cites] Radiology. 1999 May;211(2):535-40 [10228539.001]
  • [Cites] Am J Epidemiol. 2004 Nov 15;160(10):945-60 [15522851.001]
  • [Cites] Technol Cancer Res Treat. 2005 Jun;4(3):255-63 [15896081.001]
  • (PMID = 19025938.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA90437; United States / NCI NIH HHS / CA / R21 CA121568; United States / NCI NIH HHS / CA / CA121568; United States / NCI NIH HHS / CA / R01 CA090437; United States / NCI NIH HHS / CA / R01 CA090437-05; United States / NCI NIH HHS / CA / CA121568-01A2; United States / NCI NIH HHS / CA / CA090437-05; United States / NCI NIH HHS / CA / P30 CA062203; United States / NCI NIH HHS / CA / R21 CA121568-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS64002; NLM/ PMC2597344
  •  go-up   go-down


73. Zhao X, Goswami M, Pokhriyal N, Ma H, Du H, Yao J, Victor TA, Polyak K, Sturgis CD, Band H, Band V: Cyclooxygenase-2 expression during immortalization and breast cancer progression. Cancer Res; 2008 Jan 15;68(2):467-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 expression during immortalization and breast cancer progression.
  • Identification of molecular aberrations in premalignant human mammary epithelial cells (hMEC), the precursors for breast cancers, is a central goal in breast cancer biology.
  • Recent studies implicated expression of cyclooxygenase 2 (COX-2) as a marker to identify precursor cells for breast cancer.
  • Similar to immortal cells, the majority of breast cancer cell lines expressed low levels of COX-2 protein.
  • Finally, analyses of COX-2 expression in a series of specimens from reduction mammoplasty, adenosis, ductal carcinoma in situ, and infiltrating ductal carcinoma showed down-regulation of COX-2 expression during tumor progression.
  • These results show that (a) COX-2 overexpression does not seem to predict a breast cancer precursor cell and does not provide advantage for the cell to be transformed;.
  • (b) inhibition of COX-2 does not affect hMEC growth and oncogenic behavior in the conditions analyzed; and (c) COX-2 expression is decreased in breast cancer cell lines and cancer specimens as compared with normal mammary epithelial cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Res. 2008 Mar 1;68(5):1609
  • (PMID = 18199541.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA96844; United States / NCI NIH HHS / CA / CA81076; United States / NCI NIH HHS / CA / CA089393-080014; United States / NCI NIH HHS / CA / P50 CA089393; United States / NCI NIH HHS / CA / CA089393-060014; United States / NCI NIH HHS / CA / P50 CA089393-060014; United States / NCI NIH HHS / CA / CA094074-05; United States / NCI NIH HHS / CA / CA94143; United States / NCI NIH HHS / CA / P50 CA089393-080014; United States / NCI NIH HHS / CA / CA99163; United States / NCI NIH HHS / CA / CA76118; United States / NCI NIH HHS / CA / R01 CA094074-05; United States / NCI NIH HHS / CA / CA99900; United States / NCI NIH HHS / CA / CA089393-070014; United States / NCI NIH HHS / CA / P50 CA089393-070014; United States / NCI NIH HHS / CA / R01 CA094074; United States / NCI NIH HHS / CA / CA87986
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


74. Zandrino F, Calabrese M, Faedda C, Musante F: Tubular carcinoma of the breast: pathological, clinical, and ultrasonographic findings. A review of the literature. Radiol Med; 2006 Sep;111(6):773-82
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma of the breast: pathological, clinical, and ultrasonographic findings. A review of the literature.
  • PURPOSE: Tubular carcinoma of the breast is a well-differentiated adenocarcinoma.
  • MATERIALS AND METHODS: A retrospective review of 560 consecutive histologically proven carcinomas of the breast was made.
  • In three, core biopsy was made: in the first, a complex sclerosing lesion with atypical cells was suggested, in the second differential diagnosis between tubular carcinoma and sclerosing adenosis was proposed and in the third a tubular carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / ultrasonography. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896563.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 26
  •  go-up   go-down


75. Vazmitel M, Pavlovsky M, Kacerovska D, Michal M, Kazakov DV: Pseudoangiomatous stromal hyperplasia in a complex neoplastic lesion involving anogenital mammary-like glands. J Cutan Pathol; 2009 Oct;36(10):1117-20
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pseudoangiomatous stromal hyperplasia (PASH), a relatively frequent hormonal change associated with different benign and malignant processes in the breast, was only once mentioned in the literature concerning the pathology of AMLG.
  • The present case of PASH is remarkable because of its occurrence within a complex lesion evidencing the changes identical to or reminiscent of blunt duct adenosis, fibroadenoma and hidradenoma papilliferum.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adult. Breast Neoplasms / pathology. Endometrial Neoplasms / pathology. Female. Fibroadenoma / pathology. Humans. Hyperplasia. Immunohistochemistry

  • Genetic Alliance. consumer health - Pseudoangiomatous stromal hyperplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 John Wiley & Sons A/S.
  • (PMID = 19508499.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


76. Grunwald S, Heyer H, Kühl A, Schwesinger G, Schimming A, Köhler G, Ohlinger R: Radial scar/complex sclerosing lesion of the breast--value of ultrasound. Ultraschall Med; 2007 Apr;28(2):206-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radial scar/complex sclerosing lesion of the breast--value of ultrasound.
  • PURPOSE: Although benign, radial scar/complex sclerosing adenosis is a lesion which histopathologically resembles tubular carcinoma.
  • [MeSH-major] Breast Diseases / ultrasonography. Cicatrix / ultrasonography

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955394.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


77. Drosos Y, Kouloukoussa M, Østvold AC, Grundt K, Goutas N, Vlachodimitropoulos D, Havaki S, Kollia P, Kittas C, Marinos E, Aleporou-Marinou V: NUCKS overexpression in breast cancer. Cancer Cell Int; 2009;9:19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NUCKS overexpression in breast cancer.
  • A number of reports show that NUCKS is highly expressed on the level of mRNA in several human cancers, including breast cancer.
  • In this work, NUCKS expression on both RNA and protein levels was studied in breast tissue biopsies consisted of invasive carcinomas, intraductal proliferative lesions, benign epithelial proliferations and fibroadenomas, as well as in primary cultures derived from the above biopsies.
  • Specifically, in order to evaluate the level of NUCKS protein in correlation with the histopathological features of breast disease, immunohistochemistry was employed on paraffin sections of breast biopsies of the above types.
  • RESULTS: The immunohistochemical Results showed intense NUCKS staining mostly in grade I and II breast carcinomas compared to normal tissues.
  • Furthermore, NUCKS was moderate expressed in benign epithelial proliferations, such as adenosis and sclerosing adenosis, and highly expressed in intraductal lesions, specifically in ductal carcinomas in situ (DCIS).
  • RT-PCR and qRT-PCR showed an increase of NUCKS expression in cells derived from primary cultures of proliferative lesions and cancerous tissues compared to the ones derived from normal breast tissues and fibroadenomas.
  • CONCLUSION: The results show overexpression of the NUCKS protein in a number of non malignant breast lesions and cancerous tissues.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell Int. 2007;7:16 [17910753.001]
  • [Cites] Cancer Detect Prev. 1999;23(4):280-9 [10403899.001]
  • [Cites] Science. 2007 May 25;316(5828):1138-9 [17525326.001]
  • [Cites] Nat Rev Genet. 2007 May;8(5):341-52 [17440531.001]
  • [Cites] Mol Cancer. 2007;6:7 [17233903.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4741-53 [15897902.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]
  • [Cites] Int J Cancer. 1997 Oct 21;74(5):513-7 [9355973.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):873-9 [7635449.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):167-80 [7831528.001]
  • [Cites] Eur J Biochem. 1991 Mar 28;196(3):557-67 [2013279.001]
  • [Cites] FEBS Lett. 1989 Nov 20;258(1):106-8 [2591527.001]
  • [Cites] Eur J Biochem. 1989 Oct 1;184(3):529-34 [2806236.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 22;323(3):796-801 [15381070.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):759-63 [15188144.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):583-92 [14520696.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 15;142(2):145-8 [12699893.001]
  • [Cites] Haematologica. 2003 Mar;88(3):268-74 [12651264.001]
  • [Cites] Breast Cancer Res. 2003;5(2):89-95 [12631387.001]
  • [Cites] Genome Res. 2002 Oct;12(10):1517-22 [12368243.001]
  • [Cites] Mol Biol Cell. 2002 Jun;13(6):1977-2000 [12058064.001]
  • [Cites] Eur J Biochem. 2001 Apr;268(8):2430-40 [11298763.001]
  • [Cites] J Pathol. 2001 Jan;193(1):40-7 [11169514.001]
  • [Cites] Mol Pathol. 2000 Jun;53(3):118-21 [10897329.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Nov 15;233(1):81-91 [18367224.001]
  • [Cites] Proteins. 2008 Nov 15;73(3):710-8 [18491381.001]
  • [Cites] Oncologist. 2008 Apr;13(4):350-60 [18448548.001]
  • [Cites] J Pathol. 2005 Jan;205(2):248-54 [15641021.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8541-9 [15574760.001]
  • [Cites] Mol Cell. 2007 Nov 9;28(3):482-90 [17996711.001]
  • (PMID = 19664271.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2743642
  •  go-up   go-down


78. Gebauer B, Bostanjoglo M, Moesta KT, Schneider W, Schlag PM, Felix R: Magnetic resonance-guided biopsy of suspicious breast lesions with a handheld vacuum biopsy device. Acta Radiol; 2006 Nov;47(9):907-13
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance-guided biopsy of suspicious breast lesions with a handheld vacuum biopsy device.
  • PURPOSE: To evaluate a handheld vacuum-assisted device system for magnetic resonance image (MRI)-guided breast lesion biopsy.
  • MATERIAL AND METHODS: In 32 patients, a total of 42 suspicious breast lesions (mean diameter 7.5 mm for mass lesions, 11.6 mm for non-masslike diffuse lesions) seen with MRI (no suspicious changes in breast ultrasound or mammography) were biopsied (27 lateral, 15 medial) using a 10G vacuum-assisted breast biopsy device under MR guidance.
  • Histology revealed 11 lesions with ductal carcinoma in situ (DCIS) or invasive cancer, three with intermediate lesions (LCIS) and 28 with benign breast lesions (adenosis, infected hematoma).
  • In the follow-up (mean 18 months) of the histological benign lesions, no breast cancer development was observed.
  • CONCLUSION: MRI-guided breast lesion biopsy using a handheld vacuum-assisted device is a safe and effective method for the work-up of suspicious lesions seen with breast MRI without changes in mammography or ultrasound.
  • In the case of discordant histology of vacuum biopsy and breast MRI appearance, surgical excision is recommended.
  • [MeSH-major] Biopsy, Needle / instrumentation. Breast Neoplasms / pathology. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17077039.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


79. Liu H, Jiang YX, Liu JB, Zhu QL, Sun Q, Chang XY: Contrast-enhanced breast ultrasonography: imaging features with histopathologic correlation. J Ultrasound Med; 2009 Jul;28(7):911-20
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast-enhanced breast ultrasonography: imaging features with histopathologic correlation.
  • OBJECTIVE: The purpose of this study was to identify histopathologic correlates for the varied appearances of breast masses on contrast-enhanced ultrasonography (CEUS).
  • Peripheral enhancement corresponded to a DCIS component, hypercellularity or adenosis at the periphery, and low-degree cellularity, degeneration, fibrosis, or necrosis in the center.
  • CONCLUSIONS: Breast mass CEUS findings correlated with histologic features.
  • [MeSH-major] Breast Diseases / pathology. Breast Diseases / ultrasonography. Image Enhancement. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / pathology. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Contrast Media. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted. Microbubbles. Middle Aged. Sensitivity and Specificity. Software. Sulfur Hexafluoride. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19546333.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


80. Sekine K, Tsunoda-Shimizu H, Kikuchi M, Saida Y, Kawasaki T, Suzuki K: DCIS showing architectural distortion on the screening mammogram - comparison of mammographic and pathological findings. Breast Cancer; 2007;14(3):281-4
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2 cases, sclerosing adenosis was seen in the background of the DCIS.
  • CONCLUSION: It is generally accepted that architectural distortion in DCIS is due to sclerosing adenosis, but sclerosis in the interstitium around the DCIS and presence of DCIS components in Cooper's ligament proved to be the cause of architectural distortion in the cases described here.
  • [MeSH-major] Breast Neoplasms / radiography. Carcinoma, Intraductal, Noninfiltrating / radiography. Mammography / standards

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690505.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


81. Antuofermo E, Miller MA, Pirino S, Xie J, Badve S, Mohammed SI: Spontaneous mammary intraepithelial lesions in dogs--a model of breast cancer. Cancer Epidemiol Biomarkers Prev; 2007 Nov;16(11):2247-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous mammary intraepithelial lesions in dogs--a model of breast cancer.
  • IELs, found in specimens from 60 dogs, were categorized as adenosis, sclerosing adenosis, intraductal papilloma, sclerosing papilloma, ductal hyperplasia, atypical ductal hyperplasia (ADH), and ductal carcinoma in situ (DCIS; high, intermediate, and low grade).
  • Canine mammary IELs were strikingly similar to those of the human breast.
  • The frequency of IELs in the dog, their association with spontaneous mammary cancer, their pattern of ER-alpha and HER-2 expression, and their histologic resemblance to human IELs may make the dog an ideal model to study human ER-negative (both HER-2 positive and negative) breast cancer progression as well as prevention and treatment.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma in Situ / veterinary. Dog Diseases / pathology. Mammary Neoplasms, Animal / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2181-3 [17982116.001]
  • (PMID = 17982119.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Ki-67 Antigen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


82. Camp EA, Coker AL, Robboy SJ, Noller KL, Goodman KJ, Titus-Ernstoff LT, Hatch EE, Herbst AL, Troisi R, Kaufman RH, Adam E: Breast cancer screening in women exposed in utero to diethylstilbestrol. J Womens Health (Larchmt); 2009 Apr;18(4):547-52
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer screening in women exposed in utero to diethylstilbestrol.
  • PURPOSE: To determine if women exposed in utero to diethylstilbestrol (DES) are more likely than unexposed women to receive recommended or additional breast cancer screening examinations.
  • METHODS: 1994 Diethylstilbestrol-Adenosis (DESAD) cohort data are used to assess the degree of recommended compliance of breast cancer screenings found in 3140 DES-exposed and 826 unexposed women.
  • Logistic regression modeling was used to analyze mailed questionnaire data that included reported frequency over the preceding 5 years (1990-1994) of breast-self examinations (BSEs), clinical breast examinations (CBEs), and mammograms.
  • RESULTS: DES-exposed women exceeded annual recommendations for CBEs (aOR 2.20, 95% CI, 1.04-4.67) among women without a history of benign breast disease (BBD) compared with unexposed women.
  • CONCLUSIONS: The majority of DES-exposed women receive breast cancer screenings at least at recommended intervals, but over two thirds do not perform monthly BSEs.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Nurse Pract. 1999 Nov;7(11):28-34; quiz 35-6 [10887780.001]
  • [Cites] Br J Cancer. 2001 Jan 5;84(1):126-33 [11139327.001]
  • [Cites] APMIS. 2000 Dec;108(12):793-804 [11252812.001]
  • [Cites] Obstet Gynecol. 2002 Feb;99(2):197-200 [11814496.001]
  • [Cites] Curr Womens Health Rep. 2002 Oct;2(5):390-3 [12215312.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1445-57 [12359854.001]
  • [Cites] Cancer Causes Control. 2002 Oct;13(8):753-8 [12420954.001]
  • [Cites] N Engl J Med. 1971 Apr 15;284(15):878-81 [5549830.001]
  • [Cites] Public Health Rep. 1976 May-Jun;91(3):236-42 [818662.001]
  • [Cites] Clin Obstet Gynecol. 1979 Sep;22(3):689-99 [487680.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Am J Obstet Gynecol. 1981 Jul 1;140(5):579-86 [7195652.001]
  • [Cites] Clin Pediatr (Phila). 1983 Feb;22(2):139-43 [6822019.001]
  • [Cites] N Engl J Med. 1984 Nov 29;311(22):1393-8 [6493300.001]
  • [Cites] Cancer. 1988 Oct 1;62(7):1389-96 [3416278.001]
  • [Cites] Am J Public Health. 1989 Mar;79(3):340-9 [2916724.001]
  • [Cites] JAMA. 1989 May 5;261(17):2535-42 [2649703.001]
  • [Cites] Cancer. 1992 Apr 1;69(7 Suppl):2001-2 [1544107.001]
  • [Cites] J Natl Cancer Inst. 1993 Apr 7;85(7):566-70 [8455203.001]
  • [Cites] JAMA. 1993 Apr 28;269(16):2096-100 [8468763.001]
  • [Cites] Int J Gynaecol Obstet. 1994 Feb;44(2):184 [7911109.001]
  • [Cites] Am J Epidemiol. 1996 Oct 1;144(7):645-52 [8823060.001]
  • [Cites] J Community Health. 1997 Oct;22(5):387-99 [9353685.001]
  • [Cites] JAMA. 1998 Aug 19;280(7):630-4 [9718055.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1509-14 [16896041.001]
  • [Cites] J Low Genit Tract Dis. 2008 Apr;12(2):111-7 [18369304.001]
  • (PMID = 19361323.001).
  • [ISSN] 1931-843X
  • [Journal-full-title] Journal of women's health (2002)
  • [ISO-abbreviation] J Womens Health (Larchmt)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / 1-CP-21166
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  • [Other-IDs] NLM/ PMC2857514
  •  go-up   go-down


83. Kabat GC, Jones JG, Olson N, Negassa A, Duggan C, Ginsberg M, Kandel RA, Glass AG, Rohan TE: A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control; 2010 Jun;21(6):821-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer.
  • OBJECTIVE: We used a nested case-control design within a large, multi-center cohort of women who underwent a biopsy for benign breast disease (BBD) to assess the association of broad histologic groupings and specific histologic entities with risk of breast cancer.
  • METHODS: Cases were all women who had a biopsy for BBD and who subsequently developed breast cancer; controls were individually matched to cases and were women with a biopsy for BBD who did not develop breast cancer in the same follow-up interval as that for the cases.
  • The presence of multiple foci of columnar cell hyperplasia and of complex fibroadenoma without atypia was associated with a non-significantly increased risk of breast cancer, whereas sclerosing adenosis, radial scar, and papilloma showed no association with risk.
  • CONCLUSION: Our results indicate that, compared to women with normal pathology/non-proliferative disease, women with proliferative disease without atypia have a modestly increased risk of breast cancer, whereas women with atypical hyperplasia have a substantially increased risk.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):421-30 [11914619.001]
  • [Cites] N Engl J Med. 1999 Feb 11;340(6):430-6 [9971867.001]
  • [Cites] Eur J Surg Oncol. 2004 Dec;30(10):1065-8 [15522552.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):229-37 [16034008.001]
  • [Cites] Am J Surg. 2000 Dec;180(6):428-32; discussion 432-3 [11182392.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):836-41 [12766590.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2698-708 [2986821.001]
  • [Cites] Am J Epidemiol. 1988 Sep;128(3):467-77 [3414655.001]
  • [Cites] Hum Pathol. 1989 Aug;20(8):723-5 [2744746.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):1977-83 [2804888.001]
  • [Cites] JAMA. 1992 Feb 19;267(7):941-4 [1734106.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1408-14 [1540878.001]
  • [Cites] Am J Epidemiol. 1992 Mar 15;135(6):619-31 [1580238.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1258-65 [8435803.001]
  • [Cites] Epidemiol Rev. 1993;15(1):177-87 [8405202.001]
  • [Cites] N Engl J Med. 1994 Jul 7;331(1):10-5 [8202095.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):297-301 [9149887.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1453-61 [16502407.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):665-72 [16723843.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):180-7 [17154175.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):467-72 [17337650.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2671-7 [17563394.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(2):167-74 [18297395.001]
  • [Cites] Cancer. 2008 Nov 1;113(9):2415-21 [18816618.001]
  • [Cites] Breast Cancer Res Treat. 2009 Nov;118(1):1-7 [18836828.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • (PMID = 20084540.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA095661-01; United States / NCI NIH HHS / CA / R01 CA095661; United States / NCI NIH HHS / CA / R01 CA095661-01; United States / NCI NIH HHS / CA / R01-CA95661-01
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS190315; NLM/ PMC2873161
  •  go-up   go-down


84. Jiang YX, Liu H, Liu JB, Zhu QL, Sun Q, Chang XY: Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound. Ultrasound Med Biol; 2007 Dec;33(12):1873-81
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound.
  • Accurate assessment of tumor size is necessary when selecting patients for breast-conserving surgery.
  • In the study of breast contrast-enhanced ultrasound (CEUS), we found that tumor size discrepancy between CEUS and conventional ultrasound (US) existed in some breast lesions, for which the reasons are not clear.
  • Breast CEUS examinations were performed in 104 patients with breast lesions.
  • The measurement of the 104 breast tumors on conventional US was obtained and compared with the measurement on CEUS.
  • The histopathological examination of size discrepancy was performed and the margin characteristics of breast cancers with larger measurements were compared with those with unchanged measurements.
  • Among the 104 lesions (43 malignant, 60 benign, 1 borderline), the size of 27 breast cancers and one granulomatous mastitis appeared larger at CEUS.
  • Pathologic examinations of the region corresponding to the measurement discrepancy were mainly ductal carcinomas in situ (DCIS), invasive carcinoma with a DCIS component, adenosis with lobular hyperplasia in breast cancers and inflammatory cell infiltration in one granulomatous mastitis.
  • Well-defined margin characteristics were significantly different between breast cancers with larger measurements at CEUS and those with unchanged measurements of size (p = 0.002), whereas no significant difference was found between the two groups in ill-defined, spiculated, hyperechoic halo, microlobulated and angulated margins (p = 0.463, 0.117, 0.194, 0.666 and 0.780, respectively).
  • This initial study suggests that significant discrepancy of breast lesion measurement between conventional US and CEUS is more likely presented in breast cancer than benign lesions.
  • It is difficult to predict whether the size measurement of the breast cancer increases at CEUS based on the margin characteristics showed on conventional US.
  • [MeSH-major] Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Diseases / pathology. Breast Diseases / ultrasonography. Contrast Media. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Neoplasm Staging. Phospholipids. Reproducibility of Results. Sulfur Hexafluoride

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686569.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


85. Heywang-Köbrunner SH, Heinig A, Hellerhoff K, Holzhausen HJ, Nährig J: Use of ultrasound-guided percutaneous vacuum-assisted breast biopsy for selected difficult indications. Breast J; 2009 Jul-Aug;15(4):348-56
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of ultrasound-guided percutaneous vacuum-assisted breast biopsy for selected difficult indications.
  • In four of the cases preceding core biopsy was inconclusive. four invasive carcinomas, two ductal carcinoma in situ (DCIS), three papillomas, six fibroadenomas, one adenosis tumor, one hamartoma, 10 complex cysts, 16 benign changes, three fat necroses, two granulomas, three unspecific inflammatory changes are verified.
  • [MeSH-major] Breast / pathology. Breast Diseases / pathology
  • [MeSH-minor] Biopsy / methods. Breast Neoplasms / pathology. Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography. Female. Fibrocystic Breast Disease / pathology. Fibrocystic Breast Disease / radiography. Humans. Necrosis. Organ Size. Ultrasonography / methods. Vacuum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500104.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Kazakov DV, Nemcova J, Mikyskova I, Belousova IE, Vazmitel M, Michal M: Human papillomavirus in lesions of anogenital mammary-like glands. Int J Gynecol Pathol; 2007 Oct;26(4):475-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Long considered as ectopic breast tissue, anogenital mammary-like glands (MLGs) have recently been suggested to represent distinctive structures located in the anogenital area.
  • The lesions included 3 fibroadenomas, 2 adenosis tumors, 1 invasive ductal carcinoma, 1 tubulolobular carcinoma, 2 hidradenoma papilliferum with prominent cystic change rendering a cystadenoma appearance and oxyphilic metaplasia, and 7 cases of extramammary Paget disease.
  • All 3 fibroadenomas, both adenosis tumors, both hidradenoma papilliferum, and the tubulolobular carcinoma proved negative for HPV DNA.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885501.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Li JL, Wang ZL, Su L, Liu XJ, Tang J: Breast lesions with ultrasound imaging-histologic discordance at 16-gauge core needle biopsy: can re-biopsy with 10-gauge vacuum-assisted system get definitive diagnosis? Breast; 2010 Dec;19(6):446-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast lesions with ultrasound imaging-histologic discordance at 16-gauge core needle biopsy: can re-biopsy with 10-gauge vacuum-assisted system get definitive diagnosis?
  • The aim of this study was to evaluate if re-biopsy with 10-gauge vacuum-assisted biopsy (VAB) could get definitive diagnosis for breast lesions with ultrasound (US) imaging-histologic discordance at 16-gauge core needle biopsy (CNB).
  • In them, one case upgraded from adenosis to ductal carcinoma in situ (DCIS); one case upgraded from adenosis to infiltrating ductal carcinoma (IDC); one case upgraded from atypical ductal hyperplasia to IDC; two cases upgraded from intraductal papilloma to DCIS; and one case upgraded from sclerosing adenosis to invasive lobular carcinoma (ILC).
  • Re-biopsy could improve diagnostic accuracy in patients with breast lesions showing imaging-histologic discordance during CNB, and 10-gauge VAB was a valuable method to deal with re-biopsy.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology
  • [MeSH-minor] Adult. Aged. Breast / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Middle Aged. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20869243.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


88. Charfi S, Sevestre H, Dumont F, Regimbeau JM, Chatelain D: Atypical apocrine proliferation involving anogenital mammary-like glands of the perianal region. J Cutan Pathol; 2009 Oct;36 Suppl 1:52-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anogenital mammary-like glands (MLGs) are a normal constituent of the anogenital area showing similarities to breast glands.
  • Histopathological examination of the excised lesion showed atypical apocrine proliferation arising in a complex lesion with features of fibroadenoma, adenosis and hyperplastic and cystic change.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775395.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


89. Popnikolov NK, Cavone SM, Schultz PM, Garcia FU: Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells. Mod Pathol; 2005 Dec;18(12):1535-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • We evaluated the low affinity neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • Immunohistochemical staining for p75NTR was performed on paraffin sections of 122 malignant breast lesions, 28 benign lesions and the adjacent normal breast tissue.
  • The staining pattern was compared to those of myosin heavy chain and p63. p75NTR immunostain was consistently positive and compatible with p63 and myosin immunoreactivity in the myoepithelial cells of the normal mammary gland, benign breast lesions (six usual ductal hyperplasias, six specimens with sclerosing adenosis, eight intraductal papillomas, six fibroadenomas), and carcinoma in situ (18 ductal carcinomas in situ, two noninvasive papillary carcinomas, two lobular carcinomas in situ).
  • Our study shows that p75NTR is a useful marker for breast myoepithelial cells and can be used to rule out invasive disease as well as to evaluate difficult for diagnosis sclerosing lesions.
  • Our data suggest a role of neurotrophins in the development of fibroepithelial breast tumors and some of the breast carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast / pathology. Breast Neoplasms / pathology. Epithelial Cells / pathology. Muscle, Smooth / pathology. Receptor, Nerve Growth Factor / metabolism
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunoenzyme Techniques. Myosin Heavy Chains / metabolism. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258511.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, Nerve Growth Factor; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


90. Saleh F, Abdeen S: Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. J Carcinog; 2007;6:12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis.
  • BACKGROUND: Breast cancer accounts for 30.3% of all cancer types in Kuwaiti women.
  • More than half of the cases were in the right breast, and were surgically treated by total mastectomy with axillary clearance.
  • The majority of the tumours had irregular (stellate) margins, was invasive, and had a surrounding breast tissue of adenosis or fibrocystic type.
  • CONCLUSION: Breast cancer in Kuwait seems to be more aggressive than what is currently seen in Europe, North America, Australia, and parts of Asia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] J Surg Oncol. 2004 Jun 1;86(3):134-40 [15170651.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):195-208 [10068079.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):26-35 [15332092.001]
  • [Cites] Eur J Cancer Prev. 2004 Aug;13(4):307-17 [15554559.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] Kaohsiung J Med Sci. 2005 May;21(5):197-202 [15960065.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R541-54 [15987461.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):18-21 [16029321.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2535-42 [16080489.001]
  • [Cites] J Reprod Immunol. 2005 Oct;67(1-2):35-50 [16111767.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R598-604 [16168103.001]
  • [Cites] Acta Oncol. 1990;29(7):931-4 [1979748.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):944-8 [1988136.001]
  • [Cites] Acta Oncol. 1990;29(2):129-35 [2334566.001]
  • [Cites] Acta Oncol. 1989;28(6):807-10 [2611034.001]
  • [Cites] Aust N Z J Med. 1978 Dec;8(6):630-8 [285684.001]
  • [Cites] BMJ. 1988 Oct 15;297(6654):943-8 [3142562.001]
  • [Cites] Acta Pathol Jpn. 1984 Mar;34(2):229-39 [6331061.001]
  • [Cites] J Clin Oncol. 1984 Oct;2(10):1102-9 [6491696.001]
  • [Cites] Hum Pathol. 1983 Apr;14(4):368-72 [6832775.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):873-9 [7635449.001]
  • [Cites] Breast Cancer Res Treat. 1995 Aug;35(2):201-10 [7647342.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):208-14 [7831532.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Jun;16(3):203-10 [7916848.001]
  • [Cites] Surgery. 1994 Oct;116(4):605-8; discussion 608-9 [7940156.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33 [8083119.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):156-61 [8100443.001]
  • [Cites] Hematol Oncol Clin North Am. 1994 Feb;8(1):73-100 [8150784.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):307-11 [8447534.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2894-904 [9256133.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jan;170(1):97-104 [9423608.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Oncol Rep. 1999 Jan-Feb;6(1):135-8 [9864416.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):2011-7 [10213514.001]
  • [Cites] Ontogenez. 1999 Mar-Apr;30(2):130-3 [10368823.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):827-34 [10463486.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):855-61 [10548312.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):295-8 [10671674.001]
  • [Cites] Am J Surg. 2000 Feb;179(2):81-5 [10773138.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):688-96 [11041059.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):1053-7 [12168072.001]
  • [Cites] Breast Cancer Res Treat. 2002 Dec;76(3):221-36 [12462383.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):622-30 [12628841.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):61-7 [12629055.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1321-8 [12883701.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):3-17 [1313356.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):610-3 [1419596.001]
  • [Cites] Curr Opin Obstet Gynecol. 2004 Feb;16(1):49-55 [15128008.001]
  • [Cites] Breast Cancer Res Treat. 1998;52(1-3):305-19 [10066089.001]
  • (PMID = 17892570.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2169224
  •  go-up   go-down


91. Strohsnitter WC, Noller KL, Titus-Ernstoff L, Troisi R, Hatch EE, Poole C, Glynn RJ, Hsieh CC: Breast cancer incidence in women prenatally exposed to maternal cigarette smoke. Epidemiology; 2005 May;16(3):342-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer incidence in women prenatally exposed to maternal cigarette smoke.
  • Women prenatally exposed to maternal cigarette smoke may, therefore, have a lower breast cancer risk because the fetal mammary gland's exposure to maternal estrogen is decreased.
  • Associations between prenatal maternal cigarette smoke exposure and breast cancer, however, have not been observed in previous case-control studies that relied on exposure assessment after the onset of cancer.
  • METHODS: The National Cooperative DES Adenosis project was a follow-up study of health outcomes in women prenatally exposed to diethylstilbestrol (DES).
  • In the current study, the breast cancer rates are compared among 4031 women who were or were not prenatally exposed to maternal cigarette smoke.
  • The resultant relative rate (RR) is adjusted for potential confounding by other breast cancer risk factors using Poisson regression modeling.
  • RESULTS: Fetal exposure to maternal cigarette smoke appeared to be inversely associated with breast cancer incidence (RR = 0.49; 95% confidence interval [CI] = 0.24-1.03).
  • CONCLUSION: These results support the hypothesis that in utero exposure to maternal cigarette smoke reduces breast cancer incidence.
  • [MeSH-major] Breast Neoplasms / prevention & control. Maternal-Fetal Exchange. Smoking

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15824550.001).
  • [ISSN] 1044-3983
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 88891; United States / NCI NIH HHS / CP / N01 CP 01012-21; United States / NCI NIH HHS / CP / N01 CP 01288; United States / NCI NIH HHS / CP / N01 CP 01289; United States / NCI NIH HHS / CP / N01 CP 01290; United States / NIEHS NIH HHS / ES / P30 ES 10126
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


92. Trecate G, Vergnaghi D, Manoukian S, Bergonzi S, Scaperrotta G, Marchesini M, Ferranti C, Peissel B, Spatti G, Bohm S, Conti A, Costa C, Sporeni M, Podo F, Musumeci R: MRI in the early detection of breast cancer in women with high genetic risk. Tumori; 2006 Nov-Dec;92(6):517-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI in the early detection of breast cancer in women with high genetic risk.
  • AIMS AND BACKGROUND: Women with BRCA1 or BRCA2 germline mutations have an elevated risk of developing breast and/or ovarian cancer.
  • The association of breast magnetic resonance imaging (BMRI) and ultrasonography (US) with mammography (MX) and clinical breast examination (CBE) in the regular surveillance of these individuals has been proposed and seems to improve the early detection of breast cancer.
  • METHODS: Within a multicenter study started by the Istituto Superiore di Sanità (Rome), at the Istituto Nazionale Tumori of Milan (INT) we enrolled 116 women at high genetic risk for breast cancer; they were either BRCA1 or BRCA2 mutation carriers or had a strong family history of breast cancer.
  • Three false positive results were found with BMRI: 1 case was considered suspect but related to hormonal influences; 1 case with the same pattern was sent for second-look US, which gave a negative result and BMRI review after 6 months showed normalization of the parenchyma; in the third case histology revealed the presence of adenosis.
  • In order to avoid unnecessary biopsies we believe that the combination of BMRI and conventional imaging can be very useful in screening women with a high genetic risk of breast cancer, especially with second-look evaluation by means of US when BMRI yields the only positive diagnostic result.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Magnetic Resonance Imaging. Mass Screening / methods. Population Surveillance


93. Sardanelli F, Fausto A, Esseridou A, Di Leo G, Kirchin MA: Gadobenate dimeglumine as a contrast agent for dynamic breast magnetic resonance imaging: effect of higher initial enhancement thresholds on diagnostic performance. Invest Radiol; 2008 Apr;43(4):236-42
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gadobenate dimeglumine as a contrast agent for dynamic breast magnetic resonance imaging: effect of higher initial enhancement thresholds on diagnostic performance.
  • RATIONALE AND OBJECTIVE: Gadobenate dimeglumine (Gd-BOPTA), a high-relaxivity contrast agent, has been recently proposed for dynamic MR imaging of the breast.
  • The objective of this study was to optimize the diagnostic performance of Gd-BOPTA-enhanced dynamic breast MR imaging by using adjusted initial enhancement thresholds.
  • METHODS: Thirty-four patients with 36 breast lesions (malignant/benign = 28/8) underwent dynamic breast MRI with 0.1 mmol/kg Gd-BOPTA and 120-second time resolution.
  • Three fibroadenomas, 1 adenosis, and 1 fibrosis were false positive with standard thresholds but true negatives with adjusted thresholds.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Meglumine / analogs & derivatives. Organometallic Compounds

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340247.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 15G12L5X8K / gadobenic acid; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


94. Scurry J, van der Putte SC, Pyman J, Chetty N, Szabo R: Mammary-like gland adenoma of the vulva: review of 46 cases. Pathology; 2009;41(4):372-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unusual architectural patterns resembled breast lesions such as erosive adenomatosis, sclerosing adenosis and ductal adenoma.
  • Unusual vulvar tumours, which have been previously reported as erosive adenomatosis, sclerosing adenosis, papillary adenofibroma, syringocystadenoma papilliferans, etc., are variants of MLG adenomas.

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404851.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 46
  •  go-up   go-down


95. Yang GZ, Li J, Ding HY: [Nipple adenoma: report of 18 cases with review of literatures]. Zhonghua Bing Li Xue Za Zhi; 2009 Sep;38(9):614-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinicopathological and immunohistochemical features, diagnosis and differential diagnosis of nipple adenoma of the breast.
  • RESULTS: The neoplasms were localized at nipples or under the areola of breast, adherent to the epidermis, mainly composed of dilated ducts in a tubular appearance associated with fibrotic matrix.
  • CONCLUSIONS: Nipple adenoma is an infrequent type of benign breast neoplasm, presenting as sclerosing papilloma, papillomatosis or florid sclerosing adenosis.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Nipples / pathology
  • [MeSH-minor] Adult. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Keratin-5 / metabolism. Keratins / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079190.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Keratin-5; 68238-35-7 / Keratins
  •  go-up   go-down


96. Zografos GC, Zagouri F, Sergentanis TN, Panou M, Dardamanis D, Giannakopoulou G, Filippakis GM, Papadimitriou G, Stamouli S: Psychiatric disorder associated with vacuum-assisted breast biopsy clip placement: a case report. J Med Case Rep; 2008;2:332

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychiatric disorder associated with vacuum-assisted breast biopsy clip placement: a case report.
  • INTRODUCTION: Vacuum-assisted breast biopsy is a minimally invasive technique that has been used increasingly in the treatment of mammographically detected, non-palpable breast lesions.
  • Clip placement at the biopsy site is standard practice after vacuum-assisted breast biopsy.
  • CASE PRESENTATION: We present the case of a 62-year-old woman with suspicious microcalcifications in her left breast.
  • The patient was informed about vacuum-assisted breast biopsy, including clip placement.
  • Subsequently, the patient underwent vacuum-assisted breast biopsy (11 G) under local anesthesia.
  • The pathological diagnosis was of sclerosing adenosis.
  • At the 6-month mammographic follow-up, the radiologist mentioned the existence of the metallic clip in her breast.
  • Subsequently, the woman presented complaining about "being spied [upon] by an implanted clip in [her] breast" and repeatedly requested the removal of the clip.
  • The patient was referred to the specialized psychiatrist of our breast unit for evaluation.
  • CONCLUSION: This is the first report of a psychiatric disorder being brought to the fore using a vacuum-assisted breast biopsy clip.
  • Vacuum-assisted breast biopsy, and breast biopsy in general, represent a significant experience, encompassing anxiety and pain; it may thus aggravate psychiatric conditions.
  • In a modern breast unit, the evaluation of patients should be multidisciplinary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2008 May;109(2):397-402 [17653855.001]
  • [Cites] Breast. 2008 Feb;17(1):71-5 [17869106.001]
  • [Cites] World J Surg Oncol. 2007;5:53 [17501997.001]
  • [Cites] Eur J Cancer. 2003 Aug;39(12):1676-83 [12888361.001]
  • [Cites] Clin Radiol. 2006 Mar;61(3):276-81 [16488210.001]
  • [Cites] Radiology. 2003 Nov;229(2):541-4 [14595153.001]
  • [Cites] Radiology. 2003 Aug;228(2):552-4 [12819332.001]
  • [Cites] Psychoneuroendocrinology. 2007 Jan;32(1):22-35 [17092654.001]
  • (PMID = 18928549.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2579921
  •  go-up   go-down


97. Uzunova V, Murdzhev K, Paskalev G, Manolova D, Poryazova E: [Cysts of the mammary gland--surgical behavior and treatment]. Khirurgiia (Sofiia); 2010;(1):40-3
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a result of the surgical treatment of 18 patients and of the histology are found as follows: benign cysts (13), carcinoma (1), papilloma (1), sclerotic adenosis (1), ADH (1), epidermoid cyst (1).
  • [MeSH-major] Breast Cyst / pathology. Breast Cyst / surgery. Mammary Glands, Human / pathology. Mammary Glands, Human / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21972704.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


98. Diebold T, Hahn T, Solbach C, Rody A, Balzer JO, Hansmann ML, Marx A, Viana F, Peters J, Jacobi V, Kaufmann M, Vogl TJ: Evaluation of the stereotactic 8G vacuum-assisted breast biopsy in the histologic evaluation of suspicious mammography findings (BI-RADS IV). Invest Radiol; 2005 Jul;40(7):465-71
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the stereotactic 8G vacuum-assisted breast biopsy in the histologic evaluation of suspicious mammography findings (BI-RADS IV).
  • PURPOSE: The purpose of this study was to evaluate the potential of the new 8G stereotactic vacuum-assisted breast biopsy (ST-driver, Mammotome; Ethicon Endosurgery) in the histologic evaluation of BI-RADS IV microcalcifications.
  • MATERIALS AND METHODS: Fifty-eight patients with 61 mammographic BI-RADS IV microcalcifications underwent stereotactic vacuum-assisted breast biopsy (SVAB).
  • Those 2 patients showed evidence of severe bleeding into the breast tissue and operative revision had to be performed (3.5%).
  • Most frequent benign histologies were mastopathy (13), ductal hyperplasia (9), fibroadenoma (8), and sclerosing adenosis (5).
  • CONCLUSION: The 11-G SVAB has proven to be a perfect adjunct to the existing breast biopsy methods.
  • [MeSH-major] Biopsy, Needle / instrumentation. Breast / pathology. Breast Neoplasms / pathology. Mammography. Vacuum

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973139.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Dietrich D, Lesche R, Tetzner R, Krispin M, Dietrich J, Haedicke W, Schuster M, Kristiansen G: Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues. J Histochem Cytochem; 2009 May;57(5):477-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A procedure for simultaneous quantification of DNA methylation of several genes in minute amounts of sample material was developed and applied to microdissected formalin-fixed and paraffin-embedded breast tissues.
  • Ten prognostic and diagnostic epigenetic breast cancer biomarkers (PITX2, RASSF1A, PLAU, LHX3, PITX3, LIMK1, SLITRK1, SLIT2, HS3ST2, and TFF1) were analyzed in tissue samples obtained from two patients with invasive ductal carcinoma of the breast.
  • The microdissected samples were obtained from several areas within the tumor tissue, including intraductal and invasive carcinoma, adenosis, and normal ductal epithelia of adjacent normal tissue, as well as stroma, tumor infiltrating lymphocytes, and adipose tissue.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. DNA Methylation. Fixatives. Formaldehyde. Paraffin Embedding
  • [MeSH-minor] Adipose Tissue / chemistry. Adipose Tissue / pathology. Carcinoma, Ductal, Breast / chemistry. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / chemistry. Carcinoma, Intraductal, Noninfiltrating / pathology. Female. Fibrocystic Breast Disease / chemistry. Fibrocystic Breast Disease / pathology. Humans. Indicators and Reagents. Lasers. Lymphocytes, Tumor-Infiltrating / chemistry. Microdissection. Polymerase Chain Reaction / methods. Promoter Regions, Genetic. Sequence Analysis, DNA / methods. Stromal Cells / chemistry. Sulfites

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 2007 Jan;87(1):75-83 [17170740.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7430-7 [19010860.001]
  • [Cites] Adv Exp Med Biol. 2007;593:54-65 [17265716.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Apr 1;17(7):1912-5 [17276678.001]
  • [Cites] J Pathol. 2007 Mar;211(4):410-9 [17278115.001]
  • [Cites] Prostate. 2007 May 1;67(6):638-44 [17342751.001]
  • [Cites] Pathology. 2007 Jun;39(3):305-18 [17558857.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):805-15 [17226777.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3035-41 [15131040.001]
  • [Cites] Nucleic Acids Res. 2004;32(9):e71 [15150323.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4442-52 [15231653.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:44-9 [15251938.001]
  • [Cites] Methods Mol Biol. 2004;287:169-79 [15273411.001]
  • [Cites] Methods Mol Biol. 2004;287:207-18 [15273414.001]
  • [Cites] Nucleic Acids Res. 2004;32(16):e125 [15353561.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5998-6005 [15447983.001]
  • [Cites] Cancer Res. 1990 Jul 1;50(13):3832-7 [2354435.001]
  • [Cites] Cancer Res. 1991 Jan 15;51(2):624-8 [1985778.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Gene. 1995 May 19;157(1-2):261-4 [7607504.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3005-12 [15247106.001]
  • [Cites] Oncogene. 2004 Dec 2;23(56):9034-41 [15489902.001]
  • [Cites] Int J Cancer. 2005 Apr 10;114(3):414-21 [15578730.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2156-62 [15788661.001]
  • [Cites] Mol Endocrinol. 2005 Jul;19(7):1893-903 [15761027.001]
  • [Cites] Nat Rev Genet. 2005 Aug;6(8):597-610 [16136652.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Nov;5(7):471-88 [16305345.001]
  • [Cites] Mol Cancer Res. 2006 Jan;4(1):1-8 [16446401.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):255-61 [16478744.001]
  • [Cites] Int J Biol Markers. 1999 Jul-Sep;14(3):186-8 [10569142.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2777-87 [10914724.001]
  • [Cites] Prostate. 2001 Feb 15;46(3):249-56 [11170154.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3348-53 [11423985.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):605-12 [11839581.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5261-6 [11959976.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Biotechniques. 2002 Sep;33(3):632, 634, 636-49 [12238773.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):152-6 [12866415.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):923-33 [12937133.001]
  • [Cites] Prostate. 2004 Jun 15;60(1):25-31 [15129426.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3306-10 [16740751.001]
  • [Cites] Carcinogenesis. 2006 Jul;27(7):1316-22 [16513682.001]
  • [Cites] Anal Biochem. 2006 Aug 1;355(1):50-61 [16797472.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4262-9 [16908936.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6626-36 [17121881.001]
  • [Cites] Dev Biol. 2007 Jul 15;307(2):421-33 [17540357.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(11):1679-86 [17601725.001]
  • [Cites] Anal Biochem. 2007 Oct 1;369(1):120-7 [17663982.001]
  • [Cites] Nat Protoc. 2007;2(9):2265-75 [17853883.001]
  • [Cites] Adv Cancer Res. 2008;100:203-29 [18620097.001]
  • [Cites] Genome Res. 2008 Sep;18(9):1518-29 [18577705.001]
  • [Cites] Breast Cancer Res Treat. 2008 Oct;111(3):429-37 [17965955.001]
  • [Cites] Nucleic Acids Res. 2007;35(1):e4 [17135186.001]
  • (PMID = 19153192.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fixatives; 0 / Indicators and Reagents; 0 / Sulfites; 1HG84L3525 / Formaldehyde; OJ9787WBLU / hydrogen sulfite
  • [Other-IDs] NLM/ PMC2674771
  •  go-up   go-down


100. Kazakov DV, Hügel H, Vanecek T, Michal M: Unusual hyperplasia of anogenital mammary-like glands. Am J Dermatopathol; 2006 Apr;28(2):134-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anogenital mammary-like glands, although known to exist (as ectopic breast tissue) as early as 1872, have only recently been thoroughly studied and suggested to be the possible origin for various neoplastic (benign and malignant) and reactive conditions that show a striking homology with lesions in the breast.
  • When cut longitudinally, some of these tiny ducts appeared to bud from larger ductal structures, resembling so-called satellitosis in the breast and this gave a fibroadenomatous appearance to the areas.
  • In addition, there were adenosis-like areas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625075.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Carcinoembryonic Antigen; 0 / Glycolipids; 0 / Glycoproteins; 0 / S100 Proteins; 0 / milk fat globule
  •  go-up   go-down






Advertisement